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Abstract
Transcranial Doppler ultrasound (TCD) is used for the assessment of cerebral blood flow
velocity (CBFV) at the middle cerebral artery (MCA) with the assumption that diameter of
the artery does not change. Thus, CBFV is equivalent to cerebral blood flow (CBF). The
purpose of this thesis was determine if the MCA dilates during hypercapnia (HC) and/or
constricts during hypocapnia (HO) in healthy young and older adults using 3T magnetic
resonance imaging (MRI). We also determined how these changes in MCA cross-sectional
area (CSA) influence estimates of CBF and cerebrovascular reactivity (CVR) from TCD in
young and older adults. Lastly, we compared whether changes in MCA CSA mimic those at
the internal carotid artery (ICA) as assessed with duplex ultrasound during HC and HO. For
all studies, HC was induced with 6% carbon dioxide and HO with hyperventilation at 30
breaths per minute, each for five minutes. T2-weighted sagittal images of the MCA were
performed with MRI and collection of an image took approximately one minute. When
assessing the peak response there was a significant increase in MCA CSA during HC and a
decrease during HO. Using these MCA CSA values to calculate CBF resulted in a greater
percent change during each protocol compared to CBFV. Changes in MCA CSA were also
examined every minute over the five minute periods of HC and HO and significant increases
were seen within the first minute of HC while decreases during HO were not evident until
minute four. No changes in ICA CSA occurred during HC or HO. Using CBF rather than
CBFV to calculate CVR resulted in a greater CVR for each protocol. Finally, when the
response to HC was compared between young and older adults the increase in MCA CSA
was reduced in older adults compared to young. Cerebrovascular conductance was also
reduced in older adults compared to young during HC, while CVR was not different. In
summary, the diameter of the MCA changes during manipulations of carbon dioxide and
CBFV underestimates CBF and CVR. Also, CVR may not be the best metric to compare the
vasodilatory response to HC between groups.
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Chapter 1

1

Introduction

1.1 Overview
In order to maintain cerebral function, blood flow is very tightly regulated to ensure
adequate delivery of oxygen (O2) and nutrients and removal of carbon dioxide (CO2).
Over a century of experimentation has contributed to our understanding of measurement
and regulation of cerebral blood flow (CBF)(85). Despite these achievements, much work
remains and is now potentially more important than ever as cerebrovascular function may
play a role in the development of cognitive disorders such as dementia and Alzheimer’s
disease (86). For example, in the U.S., the prevalence of Alzheimer’s disease is estimated
to triple by 2050 (37). In this context, development of techniques to accurately quantify
CBF and assess cerebrovascular function is vital.
Since its introduction in 1982 (2), transcranial Doppler ultrasound (TCD) has
been used widely to quantify cerebral blood flow velocity (CBFV) during many
experimental conditions including assessment of autoregulation, metabolic regulation of
the cerebral vasculature by CO2 and O2, with exercise, and to assess disease status. With
TCD, the middle cerebral artery (MCA) is most commonly insonated. The three main
branches coming off of the circle of Willis including the anterior cerebral artery (ACA),
middle cerebral or posterior cerebral (PCA) arteries can be insonated with TCD.
Transcranial Doppler ultrasound is relatively inexpensive, has excellent time resolution,
and is quite user friendly (103) and all of these factors have made it a commonly used
tool. With TCD, since the vessel being insonated cannot be visualized, a key assumption
is that the diameter of the insonated vessel does not change; this assumption leads to the
idea that CBFV estimates CBF.
Since the experiments of Kety and Schmidt (46, 47) the effect of “high CO2” or
hypercapnia (HC) to increase CBF and “low CO2” or hypocapnia (HO) to decrease CBF
have been measured and this response is termed cerebrovascular reactivity (CVR).
Estimates of CVR have since been used to examine differences between clinical
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populations in conditions such as migraine headache (54), diabetes (18) and transient
ischemic attack (94), for example, and during healthy aging (107). Transcranial Doppler
ultrasound is one method that is used to assess CVR and this estimate is used routinely to
predict risk of stroke and transient ischemic events in individuals with carotid artery
stenosis (32) and has been associated with all-cause mortality (79). Justification for the
use of TCD to provide estimates of CBF during changing levels of end tidal CO2
(ETCO2) come from magnetic resonance imaging (MRI) studies at 1.5T which suggested
that the MCA diameter does not change during HC or HO (89, 96). However, with a
higher resolution MRI (3.0T), MCA dilation can be observed during hypoxia (106). Since
the cerebral vasculature is generally more sensitive to the partial pressure of CO2 (PaCO2)
than the partial pressure of O2 (PO2) this could suggest that at a higher resolution a
change in MCA diameter could be detected with MRI during changes in ETCO2.
Additionally, a change in diameter of the internal carotid artery (ICA), which is
the main branch that leads into the MCA, during HO and HC has been documented (104).
This is an important finding for two reasons: 1) If the ICA changes diameter during
manipulations of ETCO2 it seems unlikely that the MCA diameter remains constant. 2)
The diameter of the ICA can be determined using duplex ultrasound, which is a more
readily available technology, whereas MRI is needed to examine MCA diameter. If
changes in the ICA diameter mimic those that occur at the MCA then insonation of this
vessel could prove useful for supplying a “correction factor” to estimate diameter
changes at the MCA with changing ETCO2. Overall, this assumption that MCA diameter
is constant while ETCO2 changes must be revisited now that advancements in MRI
technology are available. This is important to establish first in a young and healthy
population and then with a healthy aging and cardiovascular disease model since TCD is
often used to estimate CVR in these groups.
The overall objectives of this research were to quantify MCA diameter reactivity,
and thereby determine whether or not TCD can adequately quantify CBF and CVR in
healthy young and older populations. The working hypothesis is that the MCA constricts
during HO and dilates during HC, leading to an underestimation of CBF and CVR with
TCD.
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Study 1. Cerebral blood flow velocity underestimates cerebral blood flow during
hypercapnia and hypocapnia.
Purpose: To determine whether the MCA constricts during HO and/or dilates
during HC and to quantify the effect of such changes on CBF.
Hypothesis: The cross-sectional area (CSA) of the MCA will change during HO
and/or HC.
Study 2. Heterogeneous patterns of vasoreactivity in the middle cerebral and
internal carotid arteries.
Purpose: To determine the time course of the change in CSA and flow of the
MCA and ICA over 5 minutes of HC and HO in healthy individuals and to study
the contributions of MCA CSA data to the estimation of CVR values.
Hypothesis: The change in CSA during HC and HO will lead to an
underestimation of CVR as traditionally calculated with CBFV. Additionally,
changes in ICA CSA will mimic changes in the MCA during HO and HC.
Study 3. Role of the middle cerebral artery and grey matter volume in
cerebrovascular changes with healthy aging.
Purpose: To assess the effect of healthy aging on MCA vasodilation,
cerebrovascular reactivity, and cerebrovascular conductance during HC and to
normalize these indices to grey matter volume.
Hypothesis: The older adults will have less of a vasodilatory response at the MCA
compared to young controls and therefore have decreased CVR and CVC.
Cerebral blood flow will be similar between young and older adults when
normalized to grey matter volume.
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1.2 Anatomy of the Cerebral Vasculature
The brain is supplied by four major arteries which eventually converge to form the circle
of Willis. This system is unique to the brain, as opposed to other organs, in that blockade
of one of these major arteries does not necessarily mean that adequate perfusion cannot
be maintained to the entire brain. Outside of the cerebral circulation, large arteries are
generally thought of as conduit vessels and arterioles as the regulator of vascular
resistance. In the brain, the larger vessels have more involvement in regulating
cerebrovascular resistance (22). For example, moving from the aorta to the pial arteries
results in a 50 to 60% reduction in systemic pressure, and estimates suggest that larger
cerebral arteries contribute anywhere from 20 to 60% of cerebrovascular resistance (22,
38).
Posteriorly, the two vertebral arteries unite intracranially to form the basilar artery
(Figures 1.1 and 1.2). More anteriorly, the carotid arteries contribute the majority of
blood supply to the brain, with each contributing approximately 40% to total perfusion
(21). From the common carotid artery there is a bifurcation and the external carotid artery
supplies blood to the facial region while the ICA enters the cranial cavity (Figure 1.1) and
divides into four major branches: the ACA, MCA, anterior choroidal, and the posterior
communicating arteries. From the ICA on each side the anterior cerebral arteries are
joined by the anterior communicating artery and run parallel to one another to form the
rostral portion of the circle of Willis. The posterior communicating arteries are the
bridge between the rostral (carotid) circulation and the caudal (basilar) circulation and
with the basilar artery forms the caudal portion of the circle of Willis (Figure 1.2).
Interestingly, this “normal” layout of the circle of Willis was observed in just over half of
human brains in a large sample so this anatomical layout is actually quite variable (4).
The largest branch originating from the basilar artery is the PCA which supplies
the inferior and medial aspects of the temporal and occipital lobes (Figure 1.2)(21). The
MCA supplies the lateral aspects of each cerebral hemisphere whereas the ACA supplies
the medial aspects of the frontal and parietal lobes (21). From these main arteries there is
continual branching until the final superficial pial arteries penetrate into the brain matter
and are aptly named penetrating arteries (14). These arteries are surrounded by the
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Virchow-Robin space and when this space disappears the arterioles are then known as
parenchymal and become almost completely surrounded by the end-feet of glial cells
known as astrocytes. Astrocytes play a role in the regulation of CBF and will be
discussed further below (14).
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Internal
carotid artery

External
carotid artery
Common
carotid artery

Figure 1.1: The internal carotid and vertebral arteries: right side. Reproduction of a
lithograph plate from Gray's Anatomy from the 20th U.S. edition of Gray's Anatomy of
the Human Body, originally published in 1918.
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Anterior cerebral artery
Middle cerebral artery
Posterior communicating artery
Posterior cerebral artery
Basilar artery

Vertebral artery

Figure 1.2: The arteries of the base of the brain. The temporal pole of the cerebrum and a
portion of the cerebellar hemisphere have been removed on the right side. Reproduction
of a lithograph plate from Gray's Anatomy from the 20th U.S. edition of Gray's Anatomy
of the Human Body, originally published in 1918.
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1.3 Quantification of Cerebral Blood Flow and Transcranial
Doppler Ultrasound
Blood flow can be described by Poiseuille’s law [1] and this law applies during laminar
flow with Newtonian fluids in a rigid tube, where flow (Q) is proportional to the pressure
change across the system (ΔP) and the radius of the tube to the fourth power (r) and is
inversely proportional to the length of the tube (L) and viscosity of the fluid (μ). Within a
system, during acute changes in Q it is generally assumed that μ and L do not change;
thus, Q is determined by the pressure change and the change in r. The effect of r can also
be thought of in terms of vascular resistance where Q is inversely proportional to
resistance.
[1]

𝛥𝑃𝜋𝑟 4
𝑄=
8𝜇𝐿
Early on, most techniques developed to measure CBF relied on inert or
radioactive tracers and a modification of the Fick equation which states that the amount
of a tracer taken up by a tissue per unit time is equal to the product of the blood flow
through an organ and the arteriovenous difference of the tracer (16). Kety and Schmidt
(1946) were the first to use this principle with inert nitrous oxide gas as the tracer (46).
Since this time other non-invasive imaging techniques have been established and are used
widely.

1.3.1

Transcranial Doppler Ultrasound

The methods discussed above that rely on the Fick equation give an overall estimation of
CBF for the brain as a whole. In contrast, transcranial Doppler ultrasound (TCD)
measures CBFV at the larger vessels that supply the brain with blood. The premise of
Doppler ultrasound is that an ultrasound beam with a known emitted frequency makes
contact with a moving red cell and this contact changes the frequency returning to the
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receiver. Using this frequency information, which is known as the Doppler shift, the
velocity of the red cell can be calculated using the following equation:
[2]

𝑣=

𝑓𝑑 ∙ 𝑐
2𝑓𝑡 ∙ 𝑐𝑜𝑠 𝜃

Where v is velocity, fd is the detected frequency, c is the velocity of a sound wave
through tissue, ft is the transmitted frequency and θ is the angle of insonation (27). This
principle was applied to the cerebral circulation as early as 1965 (68), during surgery or
in children with open fontanels with the conventionally applied frequency of 5 to 10 MHz
(2). This technique was modified to be usable in adults using a frequency of 2 MHz
where there is less attenuation of signal by bone and soft tissues. This allows TCD to be
applied at windows of the skull where bone is thinner. The most commonly used window
is known as the transtemporal window of the temporal bone where TCD can be used to
examine CBFV in the ACA, MCA, and PCA which are the three main arteries off of the
circle of Willis (2). For the MCA, the first branch off of the circle of Willis (the M1
segment) is most commonly insonated and this is also the case for the A1 branch of the
ACA (77). For the posterior circulation, two portions of the PCA can be insonated
including P1, which is the segment between the basilar artery and the posterior cerebral
collateral artery, and P2, which is the portion distal to the posterior cerebral collateral
artery (103). The majority of studies examining the PCA focus on the P1 segment (78,
104). Knowledge of each of the three cerebral arteries average flow velocity, direction of
flow, and average depth are used to locate each vessel during a routine TCD examination
(103).
Quantification of CBF is possible with duplex ultrasound of the extracranial
arteries of the neck as the Doppler signal is used to quantify CBFV and B-mode images
are used to determine arterial diameter from which CBF can be calculated (61, 104). With
TCD B-mode imaging can be done but it appears to overestimate arterial diameter
compared to MRI measurements (106). Often, users of TCD assume that CBFV is
equivalent to CBF and this is based on the belief that the diameter of the intracerebral
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arteries (mainly the MCA) is constant. This assumption has been examined with MRI
during manipulations of ETCO2 and via direct observation during craniotomy. Two
studies have examined MCA diameter at 1.5T during hyperventilatory HO and found no
difference in MCA diameter during a decrease from baseline ETCO2 by ~13 mmHg (89,
96). Serrador et al. (2000) also looked at HC to an ETCO2 of ~45 mmHg and found no
change in diameter (89). In this study, at 1.5 T, the resolution of the magnet was reported
to be 0.47 mm. It is possible that changes in MCA diameter were not large enough to be
detected at this resolution. When ETCO2 was manipulated during craniotomy, the
diameter change was 1.7% with a sample size of three (28).
Together, these findings described above led most researchers to interpret CBFV
as CBF. However, conflicting evidence has been presented. For example, simultaneous
recordings of MCA CBFV and venous outflow velocity from the sphenoparietal sinus
during HC to ~55 mmHg indicated that venous outflow was higher than MCA CBFV
which indicates dilation at the MCA (97). Also, when comparing 133Xe clearance
estimates to TCD CBFV during HC with 4 and 6% CO2 (in O2) CBF determined with
133

Xe clearance was greater than TCD CBFV estimates, inferring vasodilation (15).

Lastly, Doppler power can be used to estimate vessel CSA based on the derivation of an
equation by Arts and Roevros (1972) used for determining blood flow (5). At the MCA,
when Doppler power was used as an index of CSA during hypercapnic hypoxia (end tidal
PO2 was 50 mmHg and ETCO2 was 8.5 to 9.5 mmHg above baseline), at the end of the
stimulus, a significant increase in Doppler power was noted which the authors suggest is
indicative that vasodilation had occurred (80). Notably, in this study neither HC or
hypoxia alone had an effect on Doppler power (80). Also, comparison of Doppler power
to vessel area in a flow phantom has raised questions as to whether power-based
estimates of CSA are justifiable in vivo (19). Overall, the fact that some of these findings
are inconsistent seems to indicate that the question of whether or not the MCA diameter
is constant during HC and/or HO needs to be revisited.
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1.4 Magnetic Resonance Imaging
In the context of this thesis, MRI is used for quantification of CBFV, determination of
MCA CSA, and estimation of brain volume so the focus will be on details relevant to
these techniques.
In the simplest terms, the basis for the MRI signal are the protons that lie within
the abundant hydrogen atoms throughout the human body. Hydrogen nuclei intrinsically
possess a nuclear spin that gives rise to a magnetic field for each proton. Normally these
spins are pointing randomly but within the external magnetic field of the MRI they are all
oriented in the same direction to form the net magnetization. The net magnetization is a
vector with a transverse component (perpendicular to the magnetic field) and a
longitudinal component (parallel or antiparallel to the magnet field). When a person is
placed within the MRI, the transverse components cancel out so there is no net transverse
magnetization but a longitudinal component is generated because there are more spins
parallel to the field than antiparallel. However, no signal is actually generated until these
spins are tipped away by what is called a radiofrequency pulse (usually by 90˚ to tip
magnetization from fully longitudinal to fully transverse) from their original orientation;
the recovery to their equilibrium state is where the MRI signal comes from. When
magnetization is in the transverse direction the spins produce an oscillating electric
current so signal is produced. After the spins have been tipped, the recovery of the
longitudinal magnetization is described by a time constant known as T1. In the transverse
direction, the spins lose coherence (are out of phase with one another) and the
magnetization decays; this process is described by the time constant T2. An image is
formed because different types of tissue have different T1 and T2 values (83). In T2weighted images tissues with long T2 values give the largest signal intensity so they
appear to be bright. Fluids have the longest T2 while water-based tissues have longer T2
values than fat-based tissues (Figure 1.3)(65). In images with predominantly T1 contrast,
long T1 tissues give the weakest signal so in this case, the brightest pixels are associated
with short T1 values. Any tissues with more water (and thus more protons) will appear
dark and this type of scan is useful for showing anatomy (Figure 1.3) (65).
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Figure 1.3: Sagittal image of the spinal column with T2 contrast (left side) and T1
contrast (right side). Image courtesy of GE Healthcare.
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Phase contrast (PC) imaging can be used to determine CBFV and was first
described by Moran in 1982 (70). This type of MRI is based on the principle that applied
magnetic gradients introduce a phase shift in moving protons that is proportional to fluid
velocity (9). With PC MRI two acquisitions need to be performed because the phase of
the signal can depend on many factors. Therefore, it is necessary to collect one
acquisition with a pulse sequence that is relatively insensitive to flow followed by one
that is sensitive to flow over a particular range of velocities so that the two acquisitions
can be subtracted. This should remove the effect of any dephasing due to other factors.
The phase is unchanged for any protons that are not moving, thus the subtraction also
suppresses any signal from background tissue (102). The maximum measurable velocity
is a parameter selected by the operator, known as the encoding velocity (Venc), which
corresponds to a phase shift of 180° (69).
Estimates of CBFV derived from TCD have been compared to PC derived
estimates, although few studies have looked at agreement between the two modalities
beyond calculation of a correlation coefficient which is useful for detection of random
error but does not detect systematic biases (62). Baledent et al. (2006) found small to
moderate correlations between PC and TCD for peak systolic and end diastolic velocities
in the MCA and absolute values for TCD were higher than for PC (9). Valdueza et al.
(1997) also reported higher values of CBFV at rest and during hyperventilation with TCD
(96). In the only examination to date looking at CVR to HC (from 40 mmHg at baseline
to 45 mmHg) with PC MRI and TCD it was again reported that CBFV and CVR values
derived from TCD were slightly higher and proportional bias was present where there
was a larger difference between the two modalities at higher velocities (57). It remains to
be seen how TCD and PC MRI may compare when velocities are examined over a wider
range of ETCO2.
MRI can also be used to examine structural properties of the cerebral blood
vessels with angiography (magnetic resonance angiography). Magnetic resonance
angiography relies on changes in the signal due to the flow of blood through or within the
image plane. If, after the 90˚ pulse, another 180˚ pulse is applied then an image with T2
contrast can be generated that has what is known as “black blood contrast” where the
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blood appears dark and there is good contrast between the blood vessel walls and the
blood (83). In contrast, if this 180˚ pulse is not applied, then the signal from flowing
blood is visible and appears bright. This is the basis for time-of-flight magnetic resonance
angiography (12).
Brain volume quantification is a technique used to detect structural differences of
different brain tissues (grey matter, white matter, etc.) while discounting differences in
positioning and larger scale differences in volume (6). The steps for determination of
brain volume involve spatially normalizing a T1-weighted image of an individual brain to
the group template. This process is a registration so that local areas stretch and compress
with respect to one another to match the template image. The image is then segmented
into tissue classes (gray matter, white matter and cerebrospinal fluid) and smoothed. This
type of analysis has been applied to many areas of research. For example, the negative
linear association grey matter volume and age has been characterized with this
methodology (31).

15

1.5 Regulation of Cerebral Blood Flow
The regulation of CBF is complex and is dependent on many factors including the
perfusion pressure of the brain, arterial blood gases, metabolic factors involved with
neurovascular coupling, and the autonomic nervous system (105).

1.5.1

Carbon Dioxide

It is well established that alterations in PaCO2 have an effect on cerebral vessels that is
unique to the cerebral circulation (3). Increased PaCO2 results in decreased tone in all
cerebral vessels with the smaller vessels being most responsive. Hypocapnia causes a
similar increase in tone in cerebral vessels of all sizes (100). Hypercapnia produces an
increase in CBF that was first reported to be approximately 75% during inhalation of 5 to
7% CO2 (47). Conversely, a decrease in PaCO2 causes a decrease in CBF which was first
documented to be 32% during active hyperventilation (46). In general, during HO CBF
decreases 2 to 3% per mmHg decrease in PaCO2 to a minimum level of ~10 to 15 mmHg.
During HC the increase in CBF is approximately 3 to 4 % per mmHg increase in PaCO2
with its highest level at 10 to 20 mmHg above baseline (13). It was originally unclear
whether PaCO2 itself was the stimulus for the change in CBF or whether the
accompanying pH change initiated the response. Human studies ruled out the effect of
arterial pH on vessel diameter (36, 53). Direct observation of pial arterioles in an
anesthetized cat model have shown that the effect of CO2 is mediated by a change in pH
of the extracellular fluid (cerebrospinal fluid) rather than a change in PaCO2 (51).
The mechanism through which CO2/pH affects vessel tone is not entirely clear
and this is probably due to redundancy in the regulatory mechanisms. An inhibitory effect
of protons on voltage dependent calcium channels has been suggested whereby their
activation prevents calcium entry into the vascular smooth muscle cell (101).
Additionally, potassium (K+) channels have been proposed to play a role where their
activation leads to hyperpolarization of the membrane, inhibition of calcium channels and
vasodilation (73). Based on animal work, four types of K+ channels have been identified
on cerebral vessels including inward rectifier K+ channels, delayed rectifier K+ channels,
ATP-sensitive K+ channels, and calcium-sensitive K+ channels (50). Of these, ATP-
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sensitive K+ channels and calcium activated K+ channels likely play a major role (59). In
animal studies, only combined inhibition of ATP-sensitive K+ channels and calcium
activated K+ channels abolished hypercapnic vasodilation (59).
In addition to a direct action on various ion channels, it is possible that CO2/pH
exerts effects on cerebral vessels through vasoactive mediators. Nitric oxide (NO) likely
plays a role in the flow response to HC since its blockade reduces the response (88, 99).
Exogenous administration of a NO donor also increases the response to HC and
diminishes the response to HO in humans (55). It appears that the source of NO, at least
in a rodent model, is neuronal NO synthase, rather than the endothelium (58). However,
there are also contradictory data that minimize the role that NO plays on CVR to CO2.
Ide et al. (2007) reported that blockade of NO had no effect on the CBFV response to HC
(42). It is possible that this is due to compensatory dilatory mechanisms that are
upregulated when NO is blocked. Additionally, when nitrite and nitrate levels were
examined (as surrogate estimates of NO), along with CVR, there was no correlation
between the measurements (66).
Evidence from pigs suggests that prostenoids may play a permissive role during
HC-induced increases in flow but on their own they are not likely the necessary mediator
for vasodilation (56). Also, in humans, administration of the cyclooxygenase inhibitor
indomethacin, reduces the CBFV response to HC (10). The conclusion from the bulk of
this evidence is that we have some ideas as to how CO2 exerts its effects on the cerebral
circulation but there are still many questions that remain unanswered.
The vasoactive response in the brain to HC and HO has been utilized to estimate
CVR and characterize cerebrovascular health. As stated previously, CVR is the change in
CBFV or CBF to a change in PaCO2 and is generally quantified as the absolute or percent
change in CBF (or CBFV) per change in PaCO2 (or ETCO2). Cerebrovascular reactivity is
thought to be an indicator of overall cerebral health and decreased CVR is associated
with several pathological states including ischemic stroke in those with carotid occlusion
(92), sleep-related disordered breathing (71), hypertension (90), multiple sclerosis (63),
Alzheimer’s disease (67), preeclampsia (87), and mortality in general (79).
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Commonly, HO CVR is assessed during hyperventilation that reduces PaCO2.
Alternatively, within the literature there are varying methodologies employed to increase
PaCO2 including rebreathing (30), breath holding (45, 81), inhalation of 2 to 6% CO2 in
air (10, 84), inhalation of 5% CO2 in 95% O2 (referred to as carbogen) (44), and
administration of acetazolamide (98), which increases PaCO2 by inhibiting the enzyme
carbonic anhydrase. Benefits and drawbacks of each of these are summarized in a review
by Fierstra et al. (2013)(23) and the authors conclude that the best option is CO2 as a
stimulus to examine CVR.

1.5.2

Blood Pressure

In general, cerebral perfusion pressure can be defined as the difference between mean
arterial pressure (MAP) and intracranial pressure. For decades, students of physiology
have been taught that CBF is protected against changes in MAP over the pressure range
of approximately 60 to 150 mmHg and this concept is known as cerebral autoregulation
(CA). Autoregulation can be examined in terms of the steady state relationship between
CBF and MAP over minutes or hours and this is known as static CA (105). Alternatively
the capacity of the cerebrovasculature to regulate the pressure-flow relationship to
transient changes in MAP over several seconds or heart beats is known as dynamic CA
(105). Based on an amalgamation of studies in patients, the concept of autoregulation was
developed and only recently has it been questioned since studies in healthy humans do
not support a system where CBF is completely protected against fluctuations in MAP
(61). Not until technology was available in the 1980s to examine beat-by-beat
measurements of MAP and CBF was it possible to examine more transient effects of
MAP on CBF. Aaslid (1989) developed a thigh cuff method where occlusion of the thigh
with rapid cuff release induced transient hypotension and it was observed that CBFV
tracked the drop in MAP but recovered more quickly (1). This finding with others led to
the development of the concept that CA acts as a high pass filter where higher frequency
BP fluctuations are transferred to the cerebral circulation whereas the circulation is
buffered against slower changes in MAP (108).
It should be noted that static versus dynamic CA are experimental rather than
physiological classifications and it is likely that the mechanisms for static and dynamic
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CA are similar. A close matching in the percent change in cerebrovascular resistance to
slower, drug-induced changes in pressure and those that occur during the drop in MAP
during thigh-cuff release has been described (95). The mechanisms through which
cerebrovascular resistance is modified to maintain cerebral perfusion pressure are unclear
at this time but likely include a combination of neurogenic, myogenic and possibly
endothelial responses (93, 105). Interestingly, based on animal studies, it has been
estimated that larger cerebral arteries contribute anywhere from 20 to 60% of
cerebrovascular resistance at rest (22, 38).
Additionally, it is important to remember that factors like BP and CO2 do not
exert their effects on the cerebral blood vessels independently. There is an interplay
between the role of MAP and CO2 on the cerebral vasculature. This was first established
in dogs where animals with a MAP of 100 mmHg had a less pronounced reaction to HC
and HO than normotensive animals and at a MAP of 50 mmHg there was no change in
CBF with HC or HO (35). Also, using CO2 as a stimulus to examine CVR may also
increase systemic MAP and possibly perfusion pressure. Battisti-Charbonney et al.
(2011) observed that below a threshold ETCO2, MAP changed little, but above this, MAP
increased linearly with ETCO2 (11). Therefore, it is important to report cerebrovascular
conductance (CVC) in an attempt to account for the effect of MAP changes during a
CVR test.

1.5.3

Neural Control

The cerebral vessels are densely innervated and the sources of innervation differ
depending on the location of the vessel. The larger blood vessels that run along the
surface of the brain are said to be innervated extrinsically by the superior cervical
ganglion, the sphenopalatine and otic ganglia, and the trigeminal ganglion (33). The
superior cervical ganglion provides sympathetic innervation and releases norepinephrine
and neuropeptide Y. The sphenopalatine and otic ganglia are responsible for
parasympathetic innervation and releases vasoactive intestinal polypetide, NO,
acetylcholine, among others. Lastly, the trigeminal ganglion is a source of sensory nerves
that contain calcitonin gene-related polypeptide, substance P, neurokinin A, and others
(33). The role of extrinsic sympathetic innervation in the brain is somewhat unclear as the
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results of blockade studies in humans have been equivocal (41, 75). In contrast,
ganglionectomy in patients with pathological conditions has resulted in increased CBF in
the majority of studies (43, 91) though it is unclear how these findings may apply in a
healthy population (48). In addition, the general consensus based on the body of literature
suggests that sympathetic innervation may serve as a protective mechanism to shift the
autoregulatory curve to higher pressure. This mechanism would protect the brain against
increased pressure with sympathetic activation (33). For example, when norepinephrine
was infused to raise pressure the change in cerebrovascular resistance that occurred was
not present when phentolamine, which is a non-selective α-receptor blocker, was infused.
Additionally, CBFV increased when norepinephrine and phentolamine were infused
together indicating that CA was impaired (49).
As pial arteries enter the brain cortical tissue they lose this extrinsic nerve supply
and receive inputs from neurons within the brain itself and this is termed “instrinsic
innervation.” These smaller vessels receive nerve afferents from areas such as the locus
coreuleus, raphe nucleus, and basal forebrain (14). However, this innervation does not
interact directly with the vessel but is instead in contact with astrocytes surrounding the
blood vessel (14). The best studied pathways involved in intrinsic innervation include
release of acetylcholine from the nucleus basalis, norepinephrine from the locus
coeruleus, and serotonin from the raphe nucleus (33). Receptors for these
neurotransmitters are located on both astrocytes and on smooth muscle and/or endothelial
cells of blood vessels (33). Complete description of these pathways is beyond the scope
of this review but it should be noted that literature in this area focuses, out of necessity,
on animal models and in some cases on brain slices. In this type of experimental set-up
blood vessels are not pressurized and do not have intraluminal flow (33). This is a
valuable experimental design to answer some questions about intrinsic innervation but
applicability to the intact human cerebrovasculature is unclear.

1.5.4

Metabolic Control

Within the brain, blood flow increases to areas that are neuronally active and this
relationship is termed neurovascular coupling. The distribution of CBF is coordinated to
increase when activity in a certain brain region increases and this response is known as
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functional hyperemia. The hyperemic response occurs within seconds and is very specific
to the region that is neuronally active (17, 74). There is a close association between
neurons, astrocytes and blood vessels within the cortex and together, these three
components comprise the neurovascular unit. Functionally, this association allows
delivery of substrates to support neuronal activation and removal of metabolic byproducts (40).
The mechanisms that are involved neurovascular regulation are still a topic of
study but it is clear that there is involvement by neurons, astrocytes and vascular cells
(40). Initially, it was proposed that a reduction in glucose or oxygen triggered by
neuronal activation may trigger the blood flow response. However, further research
indicated that it is likely synaptic signaling and not an energy deficit that triggers the flow
response (7). There are several chemical mediators that have been proposed to be
involved in stimulating the functional hyperemic response and this list includes ions,
neurotransmitters, vasoactive factors that are released in response to neurotransmitters,
and metabolic by-products (29). However, in blockade experiments, inhibiting one
candidate mediator does not completely inhibit the response which indicates that there
may be mechanistic redundancy or that some combination of the proposed mediators are
involved in the response (40). One mechanism that is fairly well established to play a role
in the hyperemic response is activation of glutamate receptors through synaptic
transmission that initiates release of NO (39) and increases calcium in astrocytic end-feet
that leads to release of other vasoactive mediators including prostenoids (40), of which
some derivatives lead to vasodilation while others cause constriction (39). Which
pathway predominates at any given time remains unclear but is likely regulated by
another mediator such as lactate, adenosine, or the level of oxygen (39). From the local
area where there is an up regulation in flow associated with neuronal activation upstream
arteries also dilate to prevent a drop in microvascular pressure and avoid a ‘steal’ from
adjacent areas (22). Overall, the mechanisms involved in neurovascular coupling remain
unclear and require further study, especially in humans. The issue is further complicated
because the mechanisms of functional hyperemia may differ from one brain location to
another (40). For example, in the cerebellum CBF increases are highly dependent on NO
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synthase but in the somatosensory cortex NO synthase-related mechanisms play a less
prominent role (20).

1.6 Cerebrovascular Reactivity and Aging
As mentioned previously, CVR is decreased with many pathological conditions.
However, the evidence related to healthy aging and CVR is mixed with some studies
reporting that CVR is reduced with healthy aging (10, 25, 60), maintained (26, 72),
increased (109), or different between sexes (44, 64). These differences likely are due to a
number of factors including the age range of the subject pool, the stimulus used to assess
CVR, sex differences, and possibly the way that the data are presented.
A large scale epidemiological study was conducted by Bakker et al. (2004) that
examined CVR in adults grouped by decade up until the age of 90 reported a 0.08% per
mmHg decrease per year (8). Therefore, studies that use an older population are probably
more likely to find a difference in CVR compared to a young group. Additionally, the
literature on CVR is complicated by the use of 5% CO2 in 95% oxygen (known as
carbogen) as a stimulus (8, 44, 60). This is problematic because a constrictive effect from
the hyperoxia may counteract vasodilation due to HC (24). For example, when CVR was
determined by two imaging methods, using the blood oxygen level dependent signal and
arterial spin labelling, there was agreement between methods when CO2 in air was the
stimulus and agreement with blood oxygen level dependent imaging carbogen estimates
of CVR. However, the CVR values determined with arterial spin labelling and carbogen
did not agree with other estimates (34). Lastly, when CO2 in air is used as the stimulus,
different percentages of CO2 have been used in the literature ranging from 2% to 7% (10,
72, 76, 82, 107). This difference makes comparison between studies more challenging.
Some studies have reported that there are sex differences in CVR. Bakker et al.
(2004) examined CVR in older adults aged 55 years and older and found that CVR was
greater in men (8). Additionally, declining CVR in women with age but no effect in men
has been reported (44). Similarly, Matteis et al. (1998) reported that CVR, as assessed by
the breath-holding index, was lower in post-menopausal women compared to younger
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premenopausal women and young and older men (64). Significant differences in CVR
have also been reported across the menstrual cycle (52) yet very few studies take this into
account when choosing young female subjects.
The reporting of CVR in terms of absolute values or percent change further
complicates study findings. For example, Oudegeest-Sander et al. (2014) examined CVR
in young, elderly, and older elderly groups and found no difference in CVR expressed in
relative terms but a difference in absolute values (76). Since there is no standardized
metric that is preferred then both absolute and relative CVR should be presented. Lastly,
the majority of studies described here have utilized TCD, and therefore, have measured
CBFV not CBF. If the MCA dilates during HC and/or constricts during HO to a different
extent in young and older subjects then using CBFV alone may disguise any differences
between the groups. In summary, the question of whether or not aging is related to
diminished CVR should be revisited due to the limitations in the previous research
described above.
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Chapter 2

2

Cerebral blood flow velocity underestimates cerebral
blood flow during modest hypercapnia and hypocapnia

(Published in J Appl Physiol 117:1090-1096, 2014. Used with permission – see Appendix
C)

2.1 Introduction
The responsiveness of the cerebral circulation to altered carbon dioxide (CO2) partial
pressures has long been recognized (12) and is the basis of one method to assess
cerebrovascular health (9, 14). Alterations in vessel diameter have been observed with in
vitro preparations or craniotomy with changes in inspired CO2 at the level of the smaller
cerebral arteries including the anterior cerebral artery, the M2 segment of the middle
cerebral artery (MCA) and the intraparenchymal cerebral arterioles (1, 7). Whether or not
larger cerebral arteries constrict and/or dilate in conscious humans is important because
the standard tool for measuring cerebral hemodynamics, transcranial Doppler ultrasound
(TCD), measures cerebral blood flow velocity (CBFV) which is used as a surrogate for
cerebral blood flow (CBF). However, the change in CBFV is equivalent to the change in
CBF only if the diameter of the insonated vessel does not change. This assumption is
particularly relevant to the M1 segment of the MCA, as it is the cerebral vessel that is
most often studied using TCD. Early studies used magnetic resonance imaging (MRI)
and reported that MCA diameter did not change in response to manipulations of end-tidal
CO2 (ETCO2) (22, 25). Serrador et al. examined MCA diameter during hypercapnia (HC)
at an ETCO2 of approximately 45 mmHg and during hypocapnia (HO) at 24 mmHg in 6
subjects and found no change in either condition (22). The voxel dimensions in this case
were 0.47 x 0.47 x 5.0 mm. Valdueza et al. had 7 subjects hyperventilate to an ETCO2 of
27 mmHg and no change in MCA diameter was detected with a voxel size of 0.8 x 0.4 x
3.0 mm (25). Both of these investigations were performed at 1.5 T with limited spatial
resolution relative to higher field systems currently available.
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In contrast to MRI data (22, 25), indirect measures suggest that MCA diameter
does change across levels of ETCO2. For example, combined measures of the
hypercapnia-induced flow difference between CBFV in the MCA and the sphenoparietal
sinus (which drains the MCA) indicated a greater increase on the venous side (26). The
authors attributed this observation to MCA vasodilation (26).
Measures of CBFV as an index of CBF are challenged not only by the assumption
of constant MCA diameter, but also velocity errors. A problem inherent to the Doppler
signal is overestimation of peak values due to spectral broadening, which has a greater
impact as the angle of insonation increases (11). Spectral broadening occurs intrinsically
due to the nature of transmitting and receiving acoustic energy (8) and has been
documented with other types of Doppler ultrasound systems (11). In addition to TCD,
MRI-based phase contrast (PC) imaging can estimate CBFV based on the principle that
applied magnetic gradients induce a phase shift in moving protons that is proportional to
fluid velocity. Phase contrast imaging has been validated against a flow phantom for
estimation of total CBF through the basilar artery and internal carotid arteries and has
been used to estimate MCA CBFV (2, 15, 23). Leung et al. reported that PC-based
estimates were lower than those measured by TCD with the error attributed to Doppler
spectral broadening (15). Overall, the agreement between TCD and PC estimates of
CBFV requires further study.
The primary purpose of this study was to determine if the MCA constricts during
HO and/or dilates during HC and to quantify the impact of such changes on CBF. A
secondary purpose was to compare velocity measures from TCD to velocity measures
collected with PC MRI over a range of ETCO2 values.

2.2 Materials and Methods
In total, nineteen subjects (24 ± 2 years, 8 males) participated in this study. Subjects were
not on any medications and were non-smokers with no history of cardiovascular disease.
All subjects gave informed consent and the protocol was approved by the Health
Sciences Research Ethics Board at Western University.
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2.2.1 Experimental Protocols
Subjects participated in two testing sessions including an MRI day and a physiological
data collection (Lab) day that were matched for time of day. Subjects were asked to
refrain from alcohol, caffeine and physical activity for 12 hours prior to testing. The
protocol consisted of 5 minutes of baseline measures followed by 5 minutes of HC or HO
(assigned randomly) then a 3-4 minute recovery period. The CO2 manipulation that had
not yet been performed (HC or HO) was then completed for 5 minutes after another 5
minute baseline. To induce HC the subjects breathed air that consisted of 6% CO2, 21%
oxygen, and balanced nitrogen. For HO, participants breathed at a rate of 30 breaths per
minute guided by a metronome. The protocols were designed to increase ETCO2 by
approximately 10 mmHg during HC and decrease ETCO2 by approximately 15 mmHg
during HO.

2.2.2 Measurements
2.2.2.1 Lab Session
Heart rate was acquired from standard ECG. Finger arterial blood pressure (BP) was
measured continuously and the brachial waveform (Finometer, Finapres Medical Systems
BV, Amsterdam, The Netherlands) was corrected to brachial sphygmomanometric
values. End-tidal CO2 (CO2100C analyzer, Biopac, CA, USA) and breathing frequency
(respiratory strain gauge) were measured continuously. Cerebral blood flow velocity of
the MCA was measured in a supine position using a 2-MHz pulsed transcranial Doppler
ultrasound probe (Neurovision system, Multigon Industries, Elmsford, CA, USA). The
average depth of the ultrasound beam was 5.0 ± 0.4 cm.

2.2.2.2 MRI Session
A 3T MRI (Magnetom TIM TRIO, Siemens Medical Solutions, Erlangen, Germany) was
used for data collection. A 3D time of flight sequence was used to select the location on
the M1 segment of the right MCA to apply a T2 fast spin echo sequence and a PC
sequence that were used to determine the vessel cross-sectional area (CSA) and CBFV,
respectively. Both T2 and PC sequences were applied during baseline conditions (Pre HC
and Pre HO) and each experimental condition (HC and HO) for 9 subjects (25 ± 2 years,
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5 males). In each condition, two T2 image acquisitions were performed (approximately 1
minute per acquisition) followed by one PC acquisition (approximately 2 minutes)
followed by two more T2 acquisitions. In the MRI session for the remaining subjects 2 to
5 T2 images were taken at baseline and during HC and HO for assessment of MCA CSA.
For T2 images, used to calculate MCA CSA, (8 slices, repetition time (TR) = 3000 ms,
echo time (TE) = 100 ms, flip angle = 120°, voxel dimensions 0.4 x 0.4 x 2.0 mm3), the
pulse sequence was gated to the peak of the pulse wave from the continuous signal
derived from an MRI-compatible pulse oximeter (8600FO MRI, Nonin Medical Inc.,
Plymouth, MN, USA) as measured at the right third finger.
For the PC acquisition, which was used to determine CBFV, (TR = 24.75 ms, TE
= 6.01 ms, flip angle = 15°, voxel dimensions 0.7 x 0.7 x 3.0 mm3) 25 phases were
retroactively gated to the signal from the pulse oximeter. The velocity-encoding factor
(Venc), which is the maximum measurable velocity, was individually determined since
setting the Venc too low can result in aliasing (18). The Venc for Pre HC and Pre HO
conditions was, on average, 111 ± 14 m/s, 145 ± 13 m/s for HC, and 98 ± 14 m/s for HO.
Respiration was collected with a strain gauge around the upper abdomen.

2.2.3 Data Analysis
2.2.3.1 Lab Data
Values of heart rate, BP, breathing frequency, and mean CBFV were averaged for the 5
minute baseline periods. These measures were averaged every minute during HC and HO
and the value reported corresponds to when the maximal and minimal CSA
measurements from the MRI were recorded.

2.2.3.2 MRI Data
Figure 2.1 shows a representative baseline T2 image. Using Osirix imaging software
(Pixmeo, Bernex, Switzerland) the CSA of each MCA image was measured in triplicate
by two blinded observers. The MCA was assumed to be circular but rather than fitting a
circle to the vessel we chose to outline the lumen manually point by point for the best fit
and this was done at each operator’s discretion after training by the same investigator. An
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intra-class correlation coefficient (ICC) was calculated to examine the agreement
between the two observers. The ICC between the two observers was 0.92; thus, the
average CSA between the two observers is reported. The HC and HO CSAs are reported
as the maximal CSA for HC and the minimal CSA for HO as well as the average of all
CSAs during HC and HO. The diameter was then determined as the square root of CSA
divided by π multiplied by 2.
An index of vascular reactivity was assessed relative to the corresponding
baseline as the ∆CSA/∆ETCO2 during each of HC and HO. Cerebral blood flow was
calculated (CSA x CBFV) using TCD CBFV as the basis for CBF calculations unless
otherwise noted. Percent change (%∆) from baseline was calculated for CBF and CBFV.
Cerebrovascular reactivity (CVR) for CBF and CBFV was calculated as both absolute
and relative change (∆CBF/∆ETCO2, ∆CBFV/∆ETCO2, %∆CBF/∆ETCO2,
%∆CBFV/∆ETCO2).
Phase contrast data were assessed using cvi42 (Circle Cardiovascular Imaging,
Calgary, AB, Canada). Phases were quantified into velocities based on the Venc. The
lumen of the MCA was identified and the mean velocity for each voxel was determined
over the 25 phases. To coincide with the TCD analysis, a peak velocity for each of the 25
images was determined from the voxel with the highest velocity within the MCA and
these values were averaged over the cardiac cycle. The analysis was performed by two
blinded observers and values were averaged. The ICC between the two observers was
1.0 (p<0.001).

2.2.4 Statistical Analysis
Data are presented as mean ± standard deviation unless otherwise indicated.
SigmaStat12.0 was used for statistical analysis. All comparisons were made with a paired
t-test. Average and maximal/minimum data are reported for HC and HO. The
maximum/minimum CSA were the main outcome of interest because this represents the
maximum to which CSA changes may impact TCD estimates of CBFV. Therefore, all
calculations relating to the change in CSA relate to the maximal CSA during HC and the
minimum during HO. Bland-Altman analysis was performed to examine the spread of
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differences between PC and TCD for estimates of CBFV and CVR. The differences
between the two estimates were plotted against the corresponding means and fixed and/or
proportional biases were assessed. A one sample t-test was performed on the difference
values between the two observers, and between PC and TCD difference values, to test for
fixed bias since the differences should be equal to zero if no fixed bias exists (3). The
regression between the differences and corresponding means was plotted and a slope
different from zero was used to indicate the presence of proportional bias (3). The ICC
was also calculated to examine the agreement between PC and TCD and a value greater
than 0.8 was considered to indicate good agreement.
Cohen’s d was calculated for the change in CSA during HC and HO to provide an
estimate of the effect size. Additionally, a post hoc power analysis was performed for the
change in CSA during each of the HO and HC conditions using GPower 3.1 (6)
specifying two tails, an α-value of 0.05, the sample size, and the effect size of Cohen’s d.

2.3 Results
T2 images were collected for 19 subjects and analysis of CSA was performed on images
from 15 subjects for HO and on 13 subjects for HC for whom image quality provided
clear MCA edges. Phase contrast images of sufficient quality to determine CBFV were
obtained in 7 of 9 individuals for both the HC and HO trials and TCD CBFV was
collected in these same subjects. The average time between the Lab and MRI session was
53 ± 58 days. This estimate is variable because 13 subjects had their Lab and MRI
sessions within 29 days of one another while the other 6 had 3 to 4 months between test
dates due to the reduced availability of the MRI.
Table 2.1 illustrates the physiologic responses to HC and HO in both the
laboratory and MRI sessions. End-tidal CO2 increased during HC and decreased during
HO in each session (p<0.01 for all cases). Breathing rate was not different during HC in
the MRI or in the Lab session. By design, breathing rate was elevated compared to
baseline during HO in each session (p<0.001). Additionally, heart rate increased during
both HC and HO in the MRI and Lab sessions (p<0.05 for all cases). Blood pressure was
measured only in the Lab session and during HC, SBP and MAP increased above
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baseline (p<0.05 for both cases) while DBP remained unchanged. During HO, SBP
increased above baseline (p<0.01) while MAP and DBP remained unchanged.
During HC, CSA of the MCA increased from 5.6 ± 0.8 at baseline to a maximal
CSA of 6.5 ± 1.0 mm2 (p<0.001; Figure 2.2A) and an average CSA of 6.3 ± 0.9 mm2
(p<0.001). During HO, the CSA decreased from 5.8 ± 0.9 at baseline to a minimum of
5.3 ± 0.9 mm2 (p<0.001; Figure 2.2B) and an average CSA of 5.5 ± 0.9 mm2 (p=0.01).
For HC, Cohen’s d was 0.94 and the achieved power was 0.87. For HO, Cohen’s d was
0.50 and achieved power was 0.44. Figure 2.2 illustrates the individual patterns of
response showing a homogeneous dilatory response for all subjects during HC and
heterogeneous vasoconstriction during HO where 6 participants showed less than a 5%
change in MCA CSA. Figure 2.3 shows the mean and individual data for the relationship
between ETCO2 and CSA. The average increase during HC was 0.11 ± 0.07 mm2/mmHg
while the average decrease during HO was 0.04 ± 0.03 mm2/mmHg.
Both PC and TCD methods produced similar significant changes in CBFV during
both HC and HO stimuli. Overall, there was a strong linear association between TCD and
PC estimates of CBFV (r=0.71, p<0.001; Figure 2.4B). The limits of agreement with
Bland-Altman analysis were at -27 and 20 on the y-axis (Figure 2.4A) and 1 value fell
outside this range at approximately y=23. Bland-Altman analysis revealed no significant
fixed (mean difference -3.56 cm/s; p=0.13) or proportional biases (r=0.01; p=0.98).
However, the spread of the differences between PC and TCD produced limits of
agreement with a wide range. The ICC for CBFV was 0.83 (p<0.001).
There were no differences in CVR between CBFV estimates obtained by TCD
and PC for HC or HO (TCD: 2.42 ± 3.98 cm/s/mmHg; PC: 2.87 ± 1.63 cm/s/mmHg, for
HC p=0.33 and TCD: -1.67 ± 1.37 cm/s/mmHg; PC: -0.92 ± 1.17 cm/s/mmHg, for HO
p=0.14). There was a strong linear association between TCD and PC CVR (r=0.81,
p<0.001; Figure 2.5B). Bland-Altman analysis for CVR (Figure 2.5A) revealed one point
that fell outside the limits of agreement of -3.6 and 4.8. No fixed bias (mean difference
0.6 cm/s/mmHg; p=0.10) was observed; however, the slope of the regression line was
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different from zero (r=0.57; p=0.032), indicating proportional bias was present. The ICC
for CVR was 0.86 (p<0.001).
Cerebral blood flow, calculated from TCD CBFV and MCA CSA, increased from
baseline during HC and decreased during HO (p<0.01 for each; Figure 2.6A). The %∆
was greater for CBF than for CBFV during HC and HO (p<0.001 for each comparison;
Figure 2.6B). There was also a significant change from baseline during HC (from 219 ±
38 to 333 ± 68 ml/min; p=0.001) and HO (from 211 ± 34 to 156 ± 13 ml/min; p=0.007)
when CBF was calculated from PC CBFV and MCA CSA. Cerebrovascular reactivity
calculated from CBF was 19 ± 23 ml/min/mmHg for HC and -8 ± 6 ml/min/mmHg for
HO. Comparing %∆CBFV CVR to %∆CBF CVR revealed that the reactivity to HC and
HO was greater for %∆CBF CVR than %∆CBFV CVR (p<0.05 for both cases; Figure
2.7).
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Table 2.1: Physiological results during HC and HO in the lab and MRI.
Pre HC

HC

Pre HO

HO

End tidal carbon dioxide (mmHg)

37 ± 3

46 ± 5*

36 ± 4

23 ± 3†

Breathing rate (breaths per minute)

13 ± 3

15 ±3

13 ± 4

28 ± 1†

Heart rate (beats per minute)

63 ± 6

67 ± 7*

67 ± 11

76 ± 12†

End tidal carbon dioxide (mmHg)

39 ± 3

49 ± 5*

36 ± 4

25 ± 9†

Breathing rate (breaths per minute)

14 ± 2

16 ± 3

14 ± 3

29 ± 1†

Heart rate (beats per minute)

61 ± 9

65 ± 6*

64 ± 9

69 ± 7†

Systolic blood pressure (mmHg)

107 ± 11

112 ± 13*

110 ± 8

114 ± 9†

Diastolic blood pressure (mmHg)

69 ± 8

70 ± 10

69 ± 8

70 ± 8

Mean arterial pressure (mmHg)

82 ± 9

86 ± 10*

84 ± 7

85 ± 7

MRI

Lab
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Values are means ± SD. *p<0.05 for Pre HC versus HC. †p<0.05 for Pre HO versus HO. MRI: HC n=13, HO n=15. Lab: HC and HO
n=7. HC = hypercapnia; HO = hypocapnia.
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Table 2.2: CBFV during HC and HO obtained from TCD and PC MRI.
Pre HC

HC

Pre HO

HO

TCD CBFV (cm/s)

68 ± 9

85 ± 15*

69 ± 8

55 ± 16†

PC CBFV (cm/s)

64 ± 10

85 ± 15*

61 ± 8

51 ± 8†

Values are means ± SD. *p<0.05 for Pre HC versus HC. †p<0.05 for Pre HO versus HO. TCD and PC: HC n=7 and HO n=7. CBFV =
cerebral blood flow velocity; HC = hypercapnia; HO = hypocapnia; PC = phase contrast; TCD = transcranial Doppler ultrasound.
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Figure 2.1: Sagittal T2 baseline image through the right middle cerebral artery of a
representative subject.

47

Figure 2.2: Individual and mean changes in the CSA of the middle cerebral artery. A:
HC (n=13). B: HO (n=15). CSA = cross-sectional area; HC = hypercapnia; HO =
hypocapnia.
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Figure 2.3: Relationship between the change in ETCO2 and the change in middle
cerebral artery CSA from HO to HC. Filled squares represent mean data with standard
deviation bars and unfilled squares show individual data (n=19; n=9 with data points for
HO and HC, n=6 for HO alone, and n=4 for HC alone). CSA = cross-sectional area;
ETCO2 = end-tidal carbon dioxide; HC = hypercapnia; HO = hypocapnia.
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Figure 2.4: Bland-Altman and scatter plots comparing TCD and PC CBFV over the
range of end-tidal carbon dioxide values. Pre HC, HC, Pre HO and HO are represented
for 7 subjects for a total of 28 data points. A: Bland-Altman plot of CBFV. B: Scatter plot
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with the regression line (solid line) and 95% confidence intervals (dashed lines) for
CBFV. CBFV = cerebral blood flow velocity; PC = phase contrast; TCD = transcranial
Doppler ultrasound.
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Figure 2.5: Bland-Altman and scatter plots comparing TCD and PC CVR over the range
of end-tidal carbon dioxide values. The change from Pre HC to HC and Pre HO to HO
are represented for 7 subjects for a total of 14 data points. A: Bland-Altman plot of CVR.
B: Scatter plot with the regression line (solid line) and 95% confidence intervals (dashed
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lines) for CVR. CVR= cerebrovascular reactivity; PC = phase contrast; TCD =
transcranial Doppler ultrasound.
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Figure 2.6: A: CBF during HC and HO calculated by multiplying the cross-sectional area
of the MCA by TCD CBFV. B: Percent change in CBFV and CBF during HC and
HO.*p<0.05. CBF = cerebral blood flow; CBFV = cerebral blood flow velocity; HC =
hypercapnia; HO = hypocapnia; MCA = middle cerebral artery; TCD = transcranial
Doppler ultrasound. n=7 for all conditions.
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Figure 2.7: Cerebrovascular reactivity expressed as percent change of CBFV and CBF
divided by the change in end tidal carbon dioxide during HC and HO.*p<0.05. CBF =
cerebral blood flow; CBFV = cerebral blood flow velocity; CVR = cerebrovascular
reactivity; HC = hypercapnia; HO = hypocapnia; MCA = middle cerebral artery; TCD =
transcranial Doppler ultrasound. n=7 for all conditions.
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2.4 Discussion
This study was the first to show that MCA CSA increases by 16 ± 7% and decreases by 8
± 6% during HC and HO, respectively. Thus, using CBFV as an estimate of flow
underestimated true flow changes in the MCA. Cerebrovascular reactivity was also lower
when using CBFV compared to CBF. Additionally, there was some variability between
TCD and PC estimates of CBFV during both HC and HO conditions which was evident
by the wide limits of agreement produced from Bland Altman analysis despite the strong
ICC value.
Overall, MCA diameters calculated from measures of CSA in the current study
(2.66 ± 0.21 to 2.87 ± 0.21 mm for HC and 2.69 ± 0.20 to 2.59 ± 0.21 with HO) are
comparable to values of 2.23 mm (24) to 3.4 mm (10, 21, 22, 25, 28) from other studies
that have employed MRI. In the current analysis, the percent change in diameter with HC
was 8 ± 3 % over an average change in ETCO2 of 9 ± 4 mmHg whereas diameter
decreased 4 ± 4 % during an ETCO2 decrease of 13 ± 5 mmHg. Willie et al. (2012)
reported a change in the diameter of the internal carotid artery of approximately 20%
over a PaCO2 range of 50 mmHg (27). Thus, the current data produced a rate of diameter
change (approximately 0.4%/mmHg) over a physiologically-relevant range of ETCO2
that is consistent with that of the internal carotid artery (approximately 0.6%/mmHg)
observed over a much wider range of ETCO2.
Previously, MCA diameter was observed not to change across a similar range of
ETCO2 examined in the current study (22, 25). However, Serrador et al. (2000) used 1.5
T MRI with a voxel size of 0.47 x 0.47 x 5.00 mm giving a total voxel volume of 1.11
mm3 (22). In the current study, the resolution of the 3T system was greater with a voxel
size of 0.4 x 0.4 x 2.0 mm for a voxel volume of 0.32 mm3. The voxel volume affects not
only the resolution but also the impact of partial volume effects. In particular, the smaller
voxel volume of the 3T system used here will reduce the presence of two or more types
of tissue in one voxel where signal from one would “water down” signal from the second.
With the larger voxel volume in the previous study partial volume effects may have
minimized any detectable change (22). In addition, a higher signal-to-noise ratio was
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achieved with the 32 channel head coil and the signal-to-noise ratio is inherently two
times greater at 3 T compared to 1.5 T (4). Some variability in MCA CSA was observed
across subjects in the current study, especially during HO. The observation of a greater
dilatory response to HC versus constrictor response to HO is consistent with previous
observations of the internal carotid artery (27). We observed high between-subject
variability in the constrictor response to HO which suggests either varying sensitivity to
CO2 or that the MCA exists in a constricted state at baseline. Giller et al. (1993) also
observed variability in the response to HO upon direct observation of the MCA during
craniotomy (7). We speculate that the brain could be protected from inappropriate
vasoconstriction which could lead to damaging ischemia, particularly if it involves the
major arteries at the base of the brain. In this context, baseline flow may be the regulated
variable in the brain as opposed to the PaCO2.
In the current study no significant biases were observed when comparing TCD
and PC estimates of CBFV. Additionally, the ICC was strong indicating that variation
between the two methods in the same subject was minimal compared to variation
between subjects. However, the variability in the differences between the two methods
produced quite a spread of data, resulting in wide limits of agreement. Leung et al.
observed proportional bias with less agreement between the two methods at high levels of
CBFV during HC (15). However, in this study, proportional bias was observed only with
CVR due to one data point where CVR was highest. This indicates that TCD and PC may
not provide similar estimates of CBFV in individuals who express a large CVR response
to HC. Leung et al. suggested that one way to reduce this variability between the two
methods may be to compare the mean CBFV signal instead of the peak signal which may
reduce partial volume effects (15).
The increase in MCA CSA with HC may be influenced by the concurrent rise in
BP. In this study, mean arterial pressure increased during HC by approximately 5 ± 3%.
Under conditions of normal ETCO2 a change in BP should have minimal effect on CBF
due to intact cerebral autoregulation. However, under hypercapnic conditions dynamic
cerebral autoregulation is impaired (19). Thus, it is possible that the cerebral circulation
may respond passively to small BP changes leading to an effect on the CSA of the MCA
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during HC. Indeed, pharmacological studies indicate that larger cerebral vessels, such as
the internal carotid artery, can change diameter passively during changes in BP (16).
Based on these earlier data (16), the change in diameter in internal carotid artery diameter
that could be expected with our change in BP is approximately 3% (16) which is less than
the 8% diameter change observed. However, the study of Liu et al. was performed under
conditions of normocapnia so it is unclear how HC may affect these results (16).
This study is limited by the fact that MCA CSA and TCD measurements were
collected on different days that were, on average, 53 days apart. We attempted to
decrease day to day variability by performing data collection at the same time of day in
the separate sessions. Despite this limitation, studies suggest that TCD and PC estimates
of CBFV are reproducible over a week in the case of TCD and over 72 days for PC (5,
23). These studies are limited by the fact that they examined repeatability under
conditions of normocapnia. Few studies that have assessed the reproducibility of
cerebrovascular reactivity to carbon dioxide have produced variable findings. McDonnell
et al. found the ICC between two estimates of TCD-based CBFV change during HC
performed a week apart to be fairly strong (ICC=0.73) in one rater who had more recently
been trained, but much weaker in the other rater (ICC=0.08) (17). Additionally, BP
measurements were not taken during the MRI session.
Another limitation of the current study was that PaCO2 was not measured.
Previous studies indicate that ETCO2 overestimates PaCO2 during HC but not HO (20,
27). Regardless, ETCO2 was used in all cases so any overestimation was comparable
between TCD and PC.
Lastly, it must be noted that in a minimal number of T2 images the vessel borders
were unclear and as result were not analyzed. Respiratory-induced motion artifacts can be
problematic and were a concern for this study. All images used in this study were
carefully monitored for significant motion problems like blurring or ghosting. It is
unlikely that the image quality could be significantly improved through the use of
respiratory gating for the following reasons: (1) the significant increase in scan time
during the T2 turbo spin echo sequence used in this study could potentially introduce
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patient movement artifacts other than respiration itself, and (2) the potentially large
variation between TR periods in this acquisition would significantly alter the spin history
and introduce other unwanted magnitude and phase variances and therefore image
artifacts.
In summary, the present data support the conclusion that the CSA of the MCA
changes in response to changes in ETCO2. The response was more homogeneous across
participants during HC than HO. These data contribute to emerging evidence that
alterations in CBF due to manipulations of the arterial partial pressure of CO2 and/or the
arterial partial pressure of oxygen are not solely due to changes in the smaller arterioles
(27, 28). Therefore, caution must be applied when using CBFV as a surrogate for CBF
during conditions that manipulate concentrations of arterial gases.
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Chapter 3

3

Heterogeneous patterns of vasoreactivity in the middle
cerebral and internal carotid arteries

(Published in Am J Physiol Heart Circ Physiol. 2015 Feb 27:ajpheart.00761.2014. doi:
10.1152/ajpheart.00761.2014. [Epub ahead of print]. Used with permission – see
Appendix C)

3.1 Introduction
It is well known that the cerebral vessels demonstrate high sensitivity to levels of carbon
dioxide (CO2) (7) but the exact mechanisms of this reactivity have yet to be elucidated (1,
13, 20). The relative change in flow or flow velocity to a given change in end tidal CO2
(ETCO2) is a standard measurement known as cerebrovascular reactivity (CVR) that
reflects the health of the cerebrovascular system (11) and the risk for a future ischemic
event (15). The relative contributions of subcortical and intraparenchymal vessels to
estimates of CVR remain unknown and the reactivity is generally attributed to the pial or
intraparenchymal vessels. Yet, estimates based on the fall in pressure from the aorta
indicate that the large subcortical or cerebral arteries contribute as much as 50 to 60% to
cerebrovascular resistance (5). Thus, understanding their reactivity to changes in CO2 has
important implications for determining cerebrovascular health.
The contribution of the conduit vessels to CVR remains unclear in intact humans
due to lack of access to direct in vivo assessment of these vessels. This limitation has led
to reliance on transcranial Doppler ultrasound (TCD) to assess cerebral vasomotor
control, a method that is applied easily and provides excellent temporal resolution of
cerebral blood flow velocity (CBFV). Although the total power of the Doppler signal has
been used to account for possible changes in middle cerebral artery (MCA) crosssectional area (CSA) (12), TCD cannot quantify cerebral blood flow (CBF) because the
CSA of the insonated vessel cannot be visualized directly. Thus, CBFV is accepted as a
suitable analog of CBF. This supposition is supported by earlier magnetic resonance
imaging (MRI) studies in which changes in MCA diameter were not observed during
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hypocapnia (HO: hyperventilation to 24 mmHg (14) and 27 mmHg (18)) or hypercapnia
(HC: ETCO2 increased to 45 mmHg (14)).
Recently, we used 3T MRI and a 32 channel head-coil to enhance resolution and
observed a statistically significant change in MCA diameter of 8 ± 3% during HC
(ETCO2 increased 9 mmHg above baseline) and a decrease in diameter of 4 ± 4% during
HO (ETCO2 decreased by 13 mmHg) (4). Thus, concurrent measures of CBFV alone
using phase contrast imaging or TCD, underestimated the true CBF by as much as 20%
(4). These observations were based on assessment of the maximal CSA during five
minute periods of HC and the minimal CSA during hyperventilatory HO. These MCA
diameter changes were replicated at 7T during HC by an independent group who reported
a 7 ± 3% diameter change when ETCO2 was kept constant at 15 mmHg above each
subject’s baseline (19). The time course of dilation and the contribution of the MCA to
changes in CVR remain fundamental to gaining greater understanding of the
contributions of these vessels versus downstream segments of the vascular tree to
cerebrovascular control.
The internal carotid artery (ICA) diameter changes by approximately 20% over a
range of partial pressures of CO2 (PaCO2) from 15 to 65 mmHg while the partial pressure
of oxygen (PO2) was clamped (21). However, the timing of this response is unknown as
the diameter measures were made after 12 to 15 minutes of CO2 stimulus. Since the ICA
can be insonated by the more cost-effective and accessible method of ultrasound it would
be useful to determine if the changes in the ICA CSA during HC and HO mimic the
changes in the MCA.
The purposes of this study were to determine the time course of the change in
CSA and flow of the MCA and ICA over 5 minutes of HC and HO in healthy individuals
and to study the contributions of MCA CSA data to the estimation of CVR values. We
also estimated wall shear stress (WSS) in order to quantify how flow-mediated effects
may contribute to the vascular responses.
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3.2 Materials and Methods
Fourteen subjects (23 ± 3 years, 7 females) gave informed consent to participate in this
study that was approved by the Health Sciences Research Ethics Board at Western
University and performed in accordance with the Declaration of Helsinki. Subjects were
non-smokers, were not on any medications, and had no history of cardiovascular disease.

3.2.1 Experimental Protocols
Subjects participated in two test days: 1) a Lab day where TCD of the MCA and duplex
imaging of the ICA were performed and 2) a separate MRI day. The Lab and MRI days
were matched for time of day. Subjects were asked to refrain from alcohol, caffeine and
physical activity for 12 hours prior to testing. The protocol on each test day consisted of 5
minutes of baseline measures (Pre HC and Pre HO) followed by 5 minutes of
hypercapnia (HC) or hypocapnia (HO) (the order of which was counterbalanced across
participants) then a 3 to 4 minute recovery period to allow ETCO2 levels to return to
normal. The PO2 was not clamped during the ETCO2 manipulations. Another 5 minute
baseline was then performed followed by the ETCO2 manipulation that had yet to be
performed. For HC, subjects breathed air composed of 6% CO2, 21% oxygen, and 72%
nitrogen. Hypocapnia was induced by hyperventilation at 30 breaths per minute guided
by a metronome. Previous use of these protocols in our lab suggested that ETCO2 levels
remain fairly constant (within ~1-2 mmHg) over the 5 minutes during each manipulation
(23).

3.2.2 Measurements
3.2.2.1 Lab Session
Heart rate was acquired from standard ECG. Finger arterial blood pressure (BP) was
measured continuously (Finometer, Finapres Medical Systems BV, Amsterdam, The
Netherlands). The brachial BP waveform was corrected to brachial sphygmomanometric
values. Breathing frequency and ETCO2 were monitored continuously with a respiratory
strain gauge and a gas analyzer (ML206, ADInstruments, Colorado Springs, CO, USA)
respectively. Right middle cerebral artery velocity (MCAv) was measured in a supine
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position (2 MHz pulsed wave TCD probe; Neurovision, Multigon Industries, Elmsford,
CA, USA). The average depth of insonation was 4.8 ± 0.3 cm.
Duplex ultrasound imaging was used to record the right ICA flow velocity (ICAv)
(Doppler ultrasound, 4.7 MHz probe) continuously while a longitudinal image of the
vessel was taken every minute during baseline and each protocol (10 MHz probe; Vivid 7
system, GE Healthcare Canada, Mississauga, ON, Canada). The ICA recording site was
at least 1 cm superior to the carotid sinus. Velocity waveforms were processed to produce
an analog signal of the instantaneous weighted mean flow velocity. The 2D echo
ultrasound images were stored for analysis with EchoPAC software (GE Healthcare
Canada, Mississauga, ON, Canada).

3.2.2.2 MRI Session
A 3T MRI (Magnetom Prisma, Siemens Medical Solutions, Erlangen, Germany) was
used to image the MCA. A 3D time of flight pulse sequence was used to identify the M1
segment location for application of a T2 fast spin echo sequence (8 slices, repetition time
= 3000 ms, echo time = 96 ms, flip angle = 120°, voxel dimensions = 0.4 x 0.4 x 2.0
mm3) for image acquisition. Collection of an image took approximately one minute and
was gated to the peak of the pulse wave at the finger derived from an MRI-compatible
pulse oximeter (8600FO MRI, Nonin Medical Inc., Plymouth, MN, USA) as measured at
the right third finger. Respiration was monitored with a strain gauge around the upper
abdomen and ETCO2 data were collected as described during the Lab session.

3.2.3 Data Analysis
Three systolic and three diastolic diameters were measured for each ICA image by a
blinded observer and an average of the three was taken. The accuracy of measurement
was confirmed by a second blinded observer using images from four participants across
the range of image quality (a total of 92 images) producing an intraclass correlation
coefficient (ICC) of 0.89 (p<0.001). A mean diameter was then calculated as: mean
diameter (mm) = (2/3*diastolic diameter (mm)) + (1/3*systolic diameter (mm)). Internal
carotid artery flow (QICA) was determined as: QICA (ml/min) = ICAv (cm/s)*[π*(mean
diameter (cm)/2)2]*60 (s/min).
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From the sagittal images, the MCA CSA was measured manually in triplicate by
each of two blinded observers using Osirix imaging software (Pixmeo, Bernex,
Switzerland) (ICC of 0.96; p<0.001) and the data from both observers were averaged and
reported. An estimate of blood flow in the MCA (QMCA) was determined as: QMCA
(ml/min) = MCAv (cm/s)*CSA (cm2)*60 (s/min). The reproducibility of MCA flow
velocity responses to HC and HO has been established in our hands under laboratory and
MRI conditions, albeit with separate modalities (i.e., TCD and phase contrast imaging)
(4). Therefore, QMCA data were based on MCAv and CSA data that were collected on
separate days. When reported, the MCA diameter was calculated from the measured CSA
value. The percent change (%∆) in CSA between baseline and HC or HO time points was
also calculated for the ICA and the MCA.
Flow indices for each vessel are reported both as absolute values and as %∆ to
account for differences in baseline flow. Cerebrovascular conductance (CVC) was
calculated for the ICA and the MCA as the quotient of flow and mean arterial pressure
(MAP). CVR was calculated for both arteries as the %∆ in flow from baseline per mmHg
change in ETCO2 at each minute of the 5 minute period during HC and HO. Wall shear
stress was calculated for the MCA and the ICA at baseline and each minute of HC and
HO as: WSS (τ, dyn/cm2) = 4*η*Q/r3*π, where η is the blood viscosity (0.009 Poise), Q
is flow (ml/min) and r is the radius of the inside of the artery (cm) (3).
All variables were similar in the baseline periods of the Lab and MRI sessions so
an average of this five minute period is reported for heart rate, BP, breathing frequency,
ETCO2, MCAv, ICAv, QICA, QMCA, CVC, CVR and WSS indices. The values during HC
and HO are reported for each minute over the 5 minute period.

3.2.4 Statistical Analysis
The effect of HC or HO on the time course of MCA and ICA changes in CSA, with the
corresponding ETCO2, heart rate and respiration outcomes, were characterized first using
one-way repeated measures ANOVAs (main effect of time) (SigmaStat 12.0, Systat
Software, San Jose, CA, USA). Subsequently, the effects of HC and HO on MCA and
ICA over time were assessed using a general linear mixed ANOVA model (main effects
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of artery). Additionally, comparisons between Lab values of ETCO2, heart rate, and
respiration to MRI values over time were performed with general linear mixed ANOVA
(main effect of experimental session). The effect of HC and HO on the index of WSS was
examined using one-way repeated measures ANOVA. The probability level for statistical
significance was p<0.05 and significant main effects or interactions were assessed using
Tukey’s post hoc test. A post-hoc power analysis was performed with G*Power 3.1 (31)
specifying two tails, an α-value of 0.05, the sample size and the effect size (Cohen’s d).

3.3 Results
Clear MCA images and complete data for MCAv and QICA were obtained from 11
participants (23 ± 3 years, 5 females) during HC at baseline and sample sizes at each of
the 5 time points were: 9, 10, 9, 9, and 8, respectively. The Pre HO sample size was 9 (23
± 3 years, 4 females) and the sample sizes at each of the 5 time points were 8, 9, 8, 9, and
5, respectively.
During HC there was a main effect of time for all BP variables, heart rate,
respiration rate, ETCO2, and CVC but there was no effect of artery (Table 3.1). Thus, the
experimental stimuli and conditions were replicated for each of the two protocols within
the same session that studied the MCA and the ICA responses. When the MCA, ICA and
MRI protocols were compared there was a trend for a main effect of experimental session
for respiration rate (p=0.06) and no differences for ETCO2 or heart rate.
Compared with baseline, a main effect of time was observed during HO for heart
rate, respiration rate, and ETCO2 but not for BP variables and there was no effect of
artery for any of these variables when the ICA and MCA protocols were compared (Table
3.2). However, main effects of time and artery were observed for CVC where constriction
of the downstream vascular bed was observed in both vessels but overall levels were
greater in the ICA. During HO, there was a main effect of experimental session when
comparing the MCA, ICA and MRI protocols for ETCO2 (p=0.05) and no differences in
heart rate or respiration rate.
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Table 3.3 shows the changes in heart rate and respiration rate during HC and HO
in the MRI session. In the MRI during HC, heart rate was increased compared to baseline
at minutes 2 to 5 of HC (p<0.05). Additionally, respiration rate was increased at minutes
4 and 5 compared to minute 1 of HC (p=0.04 for each). Compared to baseline, heart rate
was elevated at all time points of HO (p<0.05) except minute 5. By design, breathing rate
was elevated at all time points in HO (p<0.001).
Figure 3.1A shows the time course of the MCA CSA response to HC. The MCA
CSA increased progressively above baseline over the five minutes of HC (p<0.05).
Compared to baseline (5.8 ± 1.1 mm2), the largest MCA CSA (6.8 ± 1.3 mm2; +14 ± 8%)
occurred at four minutes of HC. A main effect for time (p=0.05) was observed for the
ICA CSA response to HC (Figure 3.1B) but no pairwise comparisons reached
significance despite ETCO2 levels that were greater than baseline at each time point
(p<0.001). Main effects of time (p<0.001) and artery (p<0.001) were observed for
%∆ICA and %∆MCA CSA (Figure 3.1C). In terms of QICA and QMCA a main effect of
time (p<0.001) and a trend for a difference between arteries (p=0.07) were observed
during HC (Figure 3.1D).The %∆QMCA and %∆QICA increased similarly with time
(p<0.001) in each artery (Figure 3.1E).
Figure 3.2A illustrates the change in MCA CSA during HO. Compared to
baseline, the MCA CSA was reduced from baseline (5.9 ± 0.8 mm2) only at minutes four
(p=0.01 versus baseline and p=0.003 versus HO min 1) and five (5.1 ± 0.5 mm2 at HO5;
6 ± 6%; p=0.03 versus baseline and p=0.008 versus HO min 1). The ICA CSA was not
different from baseline at any time point during HO despite significant and rapid
reductions in ETCO2 (Figure 3.2B). A main effect of time (p=0.02) was observed for
%ΔCSA of the ICA and MCA during HO (Figure 3.2C). Main effects of time (p<0.001)
and artery (p=0.006) were observed for absolute QICA and QMCA values during HO
(Figure 3.2D) but not for %∆ of either value (Figure 3.2E).
During HC, a time x method interaction was observed such that the %∆MCAv
was less than %∆QMCA and this effect was present after three minutes of HC (p<0.02;
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Figure 3.3A). During HO, a main effect for time (p<0.001) was observed indicating
similar relative reductions in both MCAv and QMCA.
Compared with baseline, MCA WSS was elevated at all HC time points (p<0.01),
and time points 2, 4, and 5 were greater than 1 (p<0.03; Table 3.4). Compared with
baseline, MCA WSS was reduced at all HO time points (p<0.05). In the ICA, wall shear
stress increased progressively during HC with time points 2 to 5 minutes being different
from baseline (p<0.001) and time points 4 and 5 minutes being greater than the first
minute of HC (p<0.05). During HO the ICA WSS was reduced compared to baseline at
all time points except minute five (p<0.05).
The contributions of changes in CSA to the overall CVR outcome was examined
by using MCAv and QMCA to calculate CVR. After five minutes, CVR was 3.13 ± 1.55
%/mmHg when MCAv was used and 4.88 ± 2.46 %/mmHg using QMCA (Figure 3.4A).
This is a difference of 58 ± 25% in CVR. Using ICAv and QICA to calculate CVR during
HC resulted in very similar estimates to those calculated from QMCA after five minutes,
although the pattern of response appears to be different (using ICAv: 4.56 ± 2.02
%/mmHg and using QICA: 4.70 ± 1.93 %/mmHg at minute five; Figure 3.4A).
Hypocapnia elicited a similar CVR value at five minutes when it was calculated using
ICAv, QICA and MCAv despite a different response pattern between MCAv and estimates
based on ICAv. Additionally, CVR calculated using QMCA was smaller than any of the
other estimates indicating that failure to account for MCA CSA changes leads to an
underestimation of CVR to HO (Figure 3.4B).
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Table 3.1: Physiological responses to hypercapnia in the ICA and the MCA over time.
Time

Pre

1

2

3

4

5

Sample

(11)

(9)

(10)

(9)

(9)

(8)

Time

Artery

<0.001

0.97

0.021

0.94

<0.001

0.94

<0.001

0.48

SBP

ICA

112 ± 10

114 ± 12

115 ± 11

116 ± 13

116 ± 12

118 ± 14

(mmHg)

MCA

111 ± 12

114 ± 12

116 ± 13

117 ± 14

116 ± 13

118 ± 13

DBP

ICA

68 ± 10

66 ± 6

67 ± 6

67 ± 8

68 ± 9

70 ± 9

(mmHg)

MCA

66 ± 8

66 ± 8

67 ± 8

67 ± 9

68 ± 9

70 ± 9

MAP

ICA

82 ± 8

83 ± 7

84 ± 6

85 ± 8

86 ± 9

87 ± 9

(mmHg)

MCA

82 ± 8

83 ± 9

84 ± 8

84 ±9

86 ± 9

86 ± 9

HR

ICA

60 ± 7

63 ± 6

66 ± 8

64 ± 11

66 ± 11

62 ± 9

(bpm)

MCA

62 ± 11

67 ± 11

67 ± 9

68 ± 10

70 ± 11

66 ± 8

P-value
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Resp

ICA

15 ± 3

15 ± 3

15 ± 2

16 ± 2

16 ± 2

16 ± 1

(breaths/min)

MCA

14 ± 3

15 ± 2

15 ± 2

15 ± 3

15 ± 2

16 ± 2

ETCO2

ICA

39 ± 5

48 ± 3

49 ± 4

49 ± 5

49 ± 4

49 ± 5

(mmHg)

MCA

40 ± 4

49 ± 4

50 ± 4

51 ± 5

51 ± 5

50 ± 5

CVC

ICA

4.0 ± 1.2

4.3 ± 1.3

4.7 ± 1.3

5.0 ± 1.6

5.5 ± 2.2

4.9 ± 1.4

MCA

3.0 ± 1.0

3.8 ± 1.4

4.0 ± 1.2

4.4 ± 1.3

4.4 ± 1.3

3.9 ± 1.3

<0.001

0.50

<0.001

0.55

<0.001

0.12

(ml/min/
mmHg)

Values are mean ± standard deviation. Sample sizes are shown in brackets. No time x artery interactions were present. CVC =
cerebrovascular conductance; DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HR = heart rate; ICA = internal
carotid artery; MAP = mean arterial pressure; MCA = middle cerebral artery; Resp = respiration rate; SBP = systolic blood pressure.
Values for ICA and MCA were obtained during separate trials of the same session, acquired in varied order.
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Table 3.2: Physiological responses to hypocapnia in the ICA and the MCA over time.
Time

Pre

1

2

3

4

5

Sample

(9)

(8)

(9)

(8)

(9)

(5)

Time

Artery

0.35

0.70

0.19

0.85

0.14

0.70

<0.001

0.95

<0.001

0.93

SBP

ICA

119 ± 9

120 ± 12

121 ± 12

119 ± 15

118 ± 12

120 ± 13

(mmHg)

MCA

118 ± 12

116 ± 13

118 ± 12

116 ± 11

117 ± 13

117 ± 4

DBP

ICA

69 ± 10

69 ± 12

71 ± 11

70 ± 12

69 ± 11

71 ± 11

(mmHg)

MCA

69 ± 9

67 ± 9

68 ± 10

68 ± 9

69 ± 9

70 ± 8

MAP

ICA

87 ± 9

87 ± 11

89 ± 11

88 ± 13

87 ± 11

88 ± 11

(mmHg)

MCA

86 ± 9

84 ± 10

85 ± 10

84 ± 9

85 ± 10

87 ± 4

HR

ICA

60 ± 12

66 ± 10

62 ± 12

66 ± 12

65 ± 12

64 ± 11

(bpm)

MCA

60 ± 11

65 ± 13

65 ± 14

66 ± 15

65 ± 13

62 ± 9

Resp

ICA

15 ± 3

29 ± 1

28 ± 3

29 ± 2

29 ± 2

28 ± 5

(breaths/min)

MCA

14 ± 3

29 ± 2

29 ± 2

30 ± 1

28 ± 2

28 ± 2

P-value
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ETCO2

ICA

39 ± 3

31 ± 4

30 ± 3

29 ± 4

29 ± 3

28 ± 2

(mmHg)

MCA

39 ± 5

30 ± 4

29 ± 5

28 ± 5

27 ± 5

25 ± 4

CVC (ml/min/

ICA

3.4 ± 0.7

2.8 ± 0.3

2.5 ± 0.3

2.7 ± 0.3

2.8 ± 0.7

2.5 ± 0.4

MCA

2.7 ± 0.7

2.4 ± 0.7

2.2 ± 0.7

2.2 ± 0.5

2.0 ± 0.6

2.0 ± 0.7

<0.001

0.47

<0.001

0.023

mmHg)

Values are mean ± standard deviation. Sample sizes are shown in brackets. No time x artery interactions were present. CVC =
cerebrovascular conductance; DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HR = heart rate; ICA = internal
carotid artery; MAP = mean arterial pressure; MCA = middle cerebral artery; Resp = respiration rate; SBP = systolic blood pressure.
Values for ICA and MCA were obtained during separate trials of the same session, acquired in varied order.
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Table 3.3: Physiological variables during hypercapnia and hypocapnia in the MRI session.
Pre

1

2

3

4

5

(11)

(9)

(10)

(9)

(9)

(8)

Heart rate (bpm)

59 ± 8

62 ± 10

66 ± 12*

67 ± 10*

68 ± 10*

69 ± 10*

Respiration rate (breaths/minute)

13 ± 3

13 ± 3

13 ± 3

14 ± 2

15 ± 2†

14 ± 3†

End tidal carbon dioxide (mmHg)

37 ± 3

52 ± 2*

52 ± 2*

53 ± 2*

53 ± 2*

52 ± 1*

(9)

(8)

(9)

(8)

(9)

(5)

Heart rate (bpm)

61 ± 9

70 ± 10*

68 ± 11*

67 ± 11*

67 ± 11*

67 ± 4

Respiration rate (breaths/minute)

14 ± 3

29 ± 1*

29 ± 1*

29 ± 1*

29 ± 1*

28 ± 1*

End tidal carbon dioxide (mmHg)

37 ± 4

24 ± 5*

25 ± 6*

24 ± 6*

24 ± 6*

25 ± 6*

Hypercapnia

Hypocapnia

Values are mean ± SD. *p<0.05 compared to Pre. †p<0.05 compared to time 1. Sample sizes are in brackets.
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Table 3.4: Index of wall shear stress (dyn/cm2) during hypercapnia and hypocapnia in the internal carotid (ICA) and middle cerebral
artery (MCA).

Hypercapnia

Hypocapnia

Pre

1

2

3

4

5

3.6 ± 1.4

4.2 ± 1.6

4.7 ± 1.7*

4.8 ± 1.7*

5.0 ± 1.8*†

4.0 ± 1.0*†

MCA 19 ± 5.6

20 ± 4.4*

23 ± 6.4*†

22 ± 4.6*

23 ± 4.9*†

23 ± 6.1*†

ICA

3.0 ± 0.9

2.5 ± 0.6*

2.3 ± 0.7*

2.5 ± 0.6*

2.5 ± 1.0*

2.6 ± 0.8

MCA 17 ± 4.8

15 ± 4.9*

14 ± 5.1*

15 ± 5.4*

14 ± 5.6*

16 ± 6.9*

ICA

Values are mean ± SD. *p<0.05 compared to Pre. †p<0.05 compared to time point 1.
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Time (min)

Figure 3.1: Change in MCA and ICA indices during hypercapnia. Sample sizes at each
time point are in brackets along the x-axis. A: MCA CSA. B: ICA CSA. There was a
main effect of time (p=0.045) but no significant pairwise comparisons. C: Percent change
in CSA from baseline. D: Absolute Q. E: Percent change in Q from baseline. CSA =
cross-sectional area; CVR = cerebrovascular reactivity; ETCO2 = end tidal carbon
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dioxide; HC = hypercapnia; HO = hypocapnia; ICA = internal carotid artery; MCA =
middle cerebral artery; Q = flow. *p<0.05 compared to Pre; †p<0.05 compared to time 1;
‡p<0.05 compared to time 2.
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Time (min)

Figure 3.2: Change in MCA and ICA indices during HO. Sample sizes at each time point
are in brackets along the x-axis. A: MCA CSA. B: ICA CSA. C: Percent change in CSA
from baseline. D: Absolute Q. E: Percent change in Q from baseline. CSA = crosssectional area; CVR = cerebrovascular reactivity; ETCO2 = end tidal carbon dioxide; HC
= hypercapnia; HO = hypocapnia; ICA = internal carotid artery; MCA = middle cerebral
artery; Q = flow. *p<0.05 compared to Pre; †p<0.05 compared to time 1.
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Figure 3.3: Percent change of QMCA and MCAv during changes in ETCO2. A:
Hypercapnia. B: Hypocapnia. ETCO2 = end tidal carbon dioxide; MCAv = middle
cerebral artery flow velocity; QMCA = middle cerebral artery flow. *p<0.05 for QMCA
versus MCAv; †p<0.05 compared to time 1; ‡p<0.05 compared to time 2.
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Figure 3.4: Cerebrovascular reactivity (CVR) over five minutes calculated from ICAv,
QICA, MCAv, and QMCA during manipulations of ETCO2. A: Hypercapnia. Standard
deviation ranges are as follows: MCAv 1.02 to 1.55 %/mmHg; QMCA 1.33 to 2.46
%/mmHg; ICAv 1.39 to 2.04 %/mmHg; QICA 0.92 to 2.10 %/mmHg. B: Hypocapnia.
MCAv -1.22 to -1.65 %/mmHg; QMCA -1.11 to -1.71 %/mmHg; ICAv -1.98 to -2.92
%/mmHg; QICA -2.05 to -3.18 %/mmHg. ETCO2 = end tidal carbon dioxide; ICAv =
internal carotid artery flow velocity; MCAv = middle cerebral artery flow velocity; QICA
= internal carotid artery flow; QMCA = middle cerebral artery flow.
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3.4 Discussion
The main findings of this study are as follows: 1) The CSA of the MCA increased by the
first minute during HC, while a decrease in MCA CSA was not observed until the fourth
minute during HO. 2) No change was observed in ICA CSA during these HC or HO
stimuli despite large changes in Q, flow velocity and WSS in each vessel and condition.
3) The corresponding relative changes in QMCA and QICA were similar for both HC and
HO. 4) The percent change in MCAv was less than the percent change in QMCA during
HC but not HO. 5) Failure to account for MCA dilation during HC underestimated CVR
by 58%. These results indicate that the subcortical vessels dilate rapidly, contribute
significantly to the change in cerebral vascular conductance during HC, and are important
to the normal CVR response during HC. Additionally, the relative change in ICA flow
corresponded well to the ipsilateral change in MCA flow rate as would be expected.
Overall, the data illustrate a greater vasoreactivity of the MCA versus the ICA in
response to changes in ETCO2.
The baseline MCA CSA values observed in this study (5.8 ± 1.1 mm2), using a
different complement of participants, are nearly identical to those observed in our
previous work (5.9 ± 0.8 mm2) (4). Also, the 8 ± 3%∆ in MCA diameter during HC, and
4 ± 4%∆ during HO, of the previous study are very similar to the respective values of 8 ±
4%and 3 ± 2% in the current study. Similarly, the average ICA baseline diameter of 5.2 ±
0.5 mm is comparable to the values reported by Willie et al. of 5.2 ± 0.6 mm (21) and Liu
et al. of 4.7 ± 0.7 mm (9).
An important observation of the current study was that the rapid change in MCA
CSA following an increase in ETCO2 was not matched by concurrent ICA dilation. The
lack of change in ICA dimensions stands in contrast to the findings of Willie et al., who
observed both a dilation during iso-oxic HC and constriction during iso-oxic HO (21).
This between-study difference likely reflects the shorter stimulus used in the current
study. Specifically, ICA diameter measurements were made during the first five minutes
of the CO2 challenge of the current study but after at least 12 minutes in the Willie et al.
study. Also, the magnitude of the HC stimulus was ~30% greater (65 mmHg) in the
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Willie et al. study. Thus, the MCA appears to exert greater sensitivity to changes in
ETCO2 than the ICA.
The current observations have important implications for the study of CVR, a
measurement used often as an index of cerebrovascular health (11, 15). Many studies of
CVR take advantage of the accessible TCD method to study MCA CBFV responses to
HC (see Topicuoglu (16); Tsivgoulis et al (17) for review). A long-standing assumption
of TCD is that the diameters of the large subcortical vessels being interrogated change
little so that flow velocity is proportionate to changes in total flow. Whereas this
assumption found support using earlier MRI devices operating at 1.5 T (14, 18), the
improved resolution of current MRI technology exposed the reactivity of this conduit
vessel to changes in ETCO2. Thus, reliance on CBFV data underestimates the true change
in CBF and this, of course, would underestimate the true values of CVR during both HC
and HO. The magnitude of this error will depend on the vasodilatory sensitivity of the
MCA that may vary with age, sex, disease, etc. Further, the combined data from the
current study, our previous report (4), and that of Willie et al. (21), suggest that the
magnitude of this error may change over the duration, and possibly dose, of the ETCO2
challenge. These observations highlight the need for caution when interpreting CVR
outcomes.
In contrast to the findings during HC, MCAv did not underestimate QMCA during
HO as we previously reported (4). The current data indicate that this constrictor pattern
was delayed, relative to the more rapid dilation, not being observed until the fourth
minute of HO (Figure 3B) and even then there was not a significant difference between
the percent change in MCAv and QMCA. The slower and smaller effect of HO suggests
that the MCA exists at a heightened level of contractile state at baseline levels of ETCO2
such that its sensitivity for further constriction is diminished. This interpretation is
consistent with the exponential nature of increase in CBF during the transition from HO
to HC (4, 21). The variability in findings between studies may be due to the approach that
highlighted the peak response in our earlier report versus the time course pattern in the
current analysis. Also, inter-individual variability and the overall smaller response to HO
will add to between-study variations. Another source of variability could be the
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difference in ETCO2 between the Lab and MRI sessions. In the future, this issue could be
resolved with clamping of ETCO2 levels to ensure that the same stimulus was attained on
both the Lab and MRI day.
In the current approach, the changes in flow observed in the ICA were driven
primarily by the changes in CBFV that, in turn, resulted from dilation or constriction of
the downstream vessels. Conversely, the changes in flow at the MCA resulted from a
combination of the change in velocity (reflecting changes in downstream vascular
conductance) and the change in MCA CSA. Thus, five important conclusions relevant to
CVR assessment can be made from the current observations. First, use of velocity data
alone underestimates the change in QMCA. Second, measures of ICA flow reflect more
accurately the CVR outcome with HC than MCA mean flow velocity and CVR
calculated using QICA provides a similar estimate to that calculated from QMCA when MRI
technology is not available, at least within the timeframe of the current paradigm. Third,
the subcortical cerebral vessels, such as the MCA, contribute importantly to the CVR
outcome. Fourth, reactivity of cerebrovascular segments appears to increase when
moving from the ICA to the MCA and possibly beyond. Fifth, CVR appears to change
over time during application of a five minute stimulus and this should be considered
when quantifying CVR.
This project provides, to our knowledge, the first insight into ETCO2-induced
changes in WSS in the M1 segment of the MCA and in the ICA of humans. Of course,
calculating WSS using a derivation of the Hagen-Poiseuille equation in human pulsatile
flow ignores assumptions of laminar Newtonian fluid flowing through straight rigid
cylindrical tubes. Also, the values presented here are calculated from flow data that are
averaged over time and cannot be used to consider peak and nadir values observed during
systole and diastole. Therefore, the values of WSS presented here must be considered to
be approximates only and qualitative in nature. With these constraints, WSS increased
during HC by ~40% in the ICA and 15% in the MCA. Thus, the dilatory response in the
MCA appears to have prevented the large increase in shear stress that was present in the
ICA. Likely, a hypercapnia induced increase in flow in blood vessels downstream to the
MCA increased shear stress at the MCA that initiated the vasodilation. In addition, these
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data suggest that the ICA is relatively insensitive to acute flow-mediated dilatory stimuli.
Based on what has been documented about the time course of flow-mediated dilation in
the periphery, and in particular the brachial artery, peak dilation is observed around 60
seconds after a stimulus in young subjects (2). It appears that this same flow-mediated
mechanism does not play a role in stimulating dilation in the ICA. However, ICA dilation
does appear to be begin near the end of the five minute CO2 stimulus (Figure 1B)
consistent with the significant dilation observed in this vessel following 15 minutes of
hypercapnia (21).Therefore, it seems unlikely that flow-mediated effects play a role in
ICA dilation and at this point the reasons for this are unknown.
This study is limited by the fact that the current design could not rule out the
effects of blood pressure on our estimates of CSA and Q. Dynamic cerebral
autoregulation is reduced during HC (10) resulting in greater fluctuations in CBF with
pressure. Thus, the increase in blood pressure during HC could contribute as a stimulus
for increased flow and, perhaps, contribute to the apparent dilation at the MCA.
However, such an impact of blood pressure is unlikely in the current study because the
increase in MAP at the first minute of HC was small (from 82 ± 8 to 83 ± 8 mmHg) and a
significant dilation was already observed. Another limitation is that the MRI and Lab
sessions were performed on different days and on average, the interval between tests was
101 ± 74 days. In five subjects the two test days were separated by 22 days but an
upgrade of our MRI system resulted in a delay for the remaining participants. To assess
reproducibility, we determined CBFV CVR in one subject during HO and three subjects
(all males) during HC on two durations separated by 29 ± 24 days. The ICC between test
days was 0.81 (p<0.001). Additionally, we have compared estimates of CBFV on
separate days (TCD and phase contrast imaging) that were performed 53 ± 48 days apart
and the ICC was 0.83 (p<0.001) (4).
Additionally, we did not control for menstrual cycle in this study.
Cerebrovascular resistance may change over the course of the menstrual cycle (8), but
whether or not menstrual cycle phase alters the MCA CSA response to HC remains to be
determined. Also, we did not clamp PO2 during HC or HO. However, when measured
independently of the current study end tidal PO2 increased from 104 ± 8 to 136 ± 4
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mmHg during HC (n=4) and during HO from 116 ± 4 to 136 ± 5 mmHg during HO
(n=3). Based on the findings of Willie et al. (21) we speculate that this change in PO2
would have little effect on CBFV or CSA outcomes because an increase in arterial PO2 to
320 mmHg only decreased MCAv by ~4 cm/s on average and decreased ICA diameter by
0.03 cm. Lastly, the statistical power achieved for MCA CSA changes across minutes one
to five are as follows: 0.42, 0.35, 0.71, 0.75, and 0.34, respectively. The differences in
statistical power between the current and previous studies can be explained on the basis
of the different methodological approach that minimized variability in the previous study.
Specifically, in our previous work (4) the achieved power was 0.87 and was based on the
peak response over a five minute stimulus. In contrast, the current study focused on effect
sizes at each time point, increasing exposure to inter-individual differences in the rate of
MCA dilation. During HO, the achieved powers are less than 0.6 at all time points due to
a smaller overall response.
In summary, this study supports the conclusion that the CSA of the MCA
increases by the first minute of HC. In contrast, the change in MCA CSA during HO was
not detected until the fourth minute. Moreover, no changes in the CSA of the ICA were
detected within the five minute stimulus period. Thus, in support of our previous
findings, TCD MCAv underestimates changes in QMCA during HC but less so during HO
(4). The similar relative changes in CBF between the ICA and MCA, suggest that the use
of duplex ultrasound to evaluate ICA flow could be used as a surrogate measure of CVR
when MCA diameters are not accessible.
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Chapter 4

4

Role of the middle cerebral artery and grey matter
volume in cerebrovascular changes with healthy aging

4.1 Introduction
The cerebral vasculature is highly sensitive to alterations in the partial pressure of carbon
dioxide (PaCO2) and in general, a lesser reactivity or change in cerebral blood flow
velocity (CBFV) or cerebral blood flow (CBF) to a change in PaCO2 is indicative of
increased risk of stroke and all-cause mortality and this measure is known as
cerebrovascular reactivity (CVR) (98, 111). Age is currently the number one risk factor
for development of cerebrovascular disease (41). It is generally well established that
absolute CBFV as measured at the middle cerebral artery (MCA) with transcranial
Doppler ultrasound (TCD) is reduced with healthy aging (11, 93, 134). However, there is
conflicting evidence as to whether CVR is reduced with aging with some studies
reporting decreased CVR with age (9, 11, 34, 132), while others reported no difference
(35, 55, 88, 93). Some variability between studies can likely be attributed to different
vasodilatory stimuli ranging from 5 to 7% CO2 in room air (9, 11, 34, 35, 55, 88, 93, 132)
or 5% CO2 in 95% oxygen (9) and different modalities to acquire CBFV and CBF (TCD
(9, 11, 34, 35, 88, 93), positron emission tomography (55), xenon inhalation (132)).
Examinations of CVR in healthy aging are further complicated by the fact that the
majority of studies rely on estimates of CBFV rather than CBF. Many studies obtain
these data using TCD that targets the MCA with the assumption that the diameter of the
MCA does not change. However, we have documented with 3T magnetic resonance
imaging (MRI) in two separate groups of young healthy subjects that the diameter of the
MCA increases by approximately 8% during hypercapnia (HC) with 6% CO2 (23, 24).
Thus, at the end of five minutes of HC, CVR calculated with CBF was 58% greater than
CVR calculated from CBFV (24). With 7T MRI, a MCA diameter change of 7% with HC
of 15 mmHg above baseline has also been reported (121).
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Previous studies using TCD to examine aging and CVR have not accounted for
MCA dilation and a possible difference in the dilatory capacity of the cerebrovasculature
between young and older groups as cerebrovascular conductance (CVC) is reduced with
aging (2). There is evidence that the CBF response to HC is mediated by prostaglandins
and/or nitric oxide (NO) (11, 71). Since both of these mediators decrease with age, at
least in the periphery (36, 112), it is possible that older adults may not have the same
dilatory response at the MCA as young subjects. If this is the case, quantifying CVR with
CBF rather than CBFV may expose a difference between young and older groups that is
masked when MCA diameter changes are not taken into account. Also, it is important to
note that CVR alone does not quantify whether the dilatory capacity of the
cerebrovasculature is intact with age. If the end tidal CO2 (ETCO2) change is equivalent
between groups with HC then the change in CBF is the primary determinant of CVR.
However, an increase in CBF could be a result of a change in mean arterial pressure
(MAP) alone. Therefore, it is necessary to examine CVC in addition to CVR to quantify
cerebrovascular health with age.
Additionally, with aging, brain atrophy occurs and is more pronounced in grey
matter (GM) than white matter (WM) (67) with certain areas within GM and WM being
more affected than others (4, 21). Thus, when CBF is compared in a young population to
an older population it may be difficult to draw conclusions when the volume of the
vascular bed being perfused is unknown. Chen et al. (2011) found that regional perfusion
quantified with arterial spin labelling and cortical thickness were not closely related
throughout much of the cortex (18). However, these measurements are based on voxellevel analysis and it is not clear whether this dissociation between CBF and GM volume
holds with a more global measure of CBF, as with TCD. Therefore, the purposes of this
study were to compare the change in cross-sectional area (CSA) of the MCA during HC
in young adults (YA) to that in older healthy adults (OA) and to assess how these changes
may impact estimates of CVR. We estimated brain volume, and more specifically GM
volume, in order to determine if the reduction in CBFV and/or CBF with age is related to
a reduction in GM volume.
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4.2 Materials and Methods
Ten older subjects aged 59 to 75 years (66 ± 7 years, 5 females) and 12 younger subjects
(24 ± 4 years, range 20 to 30 years, 6 females) gave informed consent to participate in
this study that was approved by the Health Sciences Research Ethics Board at Western
University and performed in accordance with the Declaration of Helsinki. Subjects were
non-smokers who had no history of cardiovascular disease. A female OA was on 10 mg
per day of Clobazam for seizures but had not had a seizure in 13 years. Additionally, an
older male subject was on Warfarin for a blood clot that occurred five years prior. All
other subjects were not on any type of medications. All subjects were recreationally
active. Female OA reported that they were postmenopausal (and this was confirmed with
sex hormone analysis (Table 4.3)) and not on hormone replacement therapy and young
female subjects were studied in the early follicular phase of their menstrual cycle (days 1
to 6) or the low hormone phase of oral contraceptives (4 of 6 young female participants
were taking oral contraceptives).

4.2.1 Experimental Protocols
All subjects participated in a familiarization session and two experimental sessions,
including what will be referred to as an MRI day and a Lab day. During the
familiarization session all experimental protocols were thoroughly explained, subjects
practiced breathing 6% CO2, and completed the Montreal Cognitive Assessment (MoCA:
www.mocatest.org) and the Trail Making Test to assess cognitive abilities. The MoCA is
a 10-minute test that covers eight cognitive domains and is scored out of 30 where a score
less than 26 indicates mild cognitive impairment (19). The Trail Making Test consists of
Parts A and B and in Part A 25 circles are numbered from 1 to 25 and the time is
recorded while you connect the circles numerically as fast as possible. In Part B there is a
combination of 25 consecutive numbers and letters that must be connected alternately
(i.e., 1-A, 2-B, 3-C, etc.) as fast as possible. Times can then be stratified into percentiles
based on normative data (26).
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Prior to each experimental session subjects were asked to refrain from alcohol,
physical activity, and caffeine for 12 hours prior to testing. For the Lab testing session, a
blood sample was obtained after a 12-hour fast that was analyzed for blood glucose,
hemoglobin, cholesterol, triglyceride, 17-β estradiol, progesterone, and testosterone
concentrations. A small meal consisting of a granola bar and juice was then provided. For
the MRI day subjects were permitted to eat a small breakfast before the testing session.
For each day a HC trial was performed where subjects breathed air that consisted of 6%
CO2, 21% oxygen, and 72% nitrogen. Each of these HC periods consisted of
approximately three minutes of baseline and five minutes of HC. During HC the partial
pressure of oxygen was not clamped.

4.2.2 Measurements
4.2.2.1

Lab Session

Initially, three seated blood pressure (BP) measurements were taken (HEM-790-ITCAN,
Omron, Lake Forest, IL, USA). Images of the right and left common carotid artery (10
MHz probe; Vivid 7 system, GE Healthcare Canada, Mississauga, ON, Canada) were
then captured while seated in order to quantify intima-media thickness. Throughout, heart
rate was acquired from standard ECG. Arterial BP was measured with finger cuff
plethysmography (Finometer, Finapres Medical Systems BV, Amsterdam, The
Netherlands) and the brachial BPs were derived from the finger pressure waveform
corrected to manual sphygmomanometric values. Respiration rate and ETCO2 were
monitored with a strain gauge and a gas analyzer (ML206, ADInstruments, Colorado
Springs, CO, USA), respectively. In the supine position, the right MCA was insonated to
measure CBFV (2 MHz pulsed wave TCD probe; Neurovision, Multigon Industries,
Elmsford, CA, USA) with an average depth of insonation of 4.9 ± 0.4 cm in YA and 5.0
± 0.5 cm in OA.

4.2.2.2 MRI Session
MRI was performed with a 3T system (Magnetom Prisma, Siemens Medical Solutions,
Erlangen, Germany). A 3D time of flight pulse sequence was used to identify the location
on the M1 segment of the MCA for application of a T2 fast spin echo sequence (8 slices,
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repetition time = 3000 ms, echo time = 96 ms, flip angle = 120°, voxel dimensions = 0.4
x 0.4 x 2.0 mm3). The pulse sequence was gated to the peak of the pulse wave measured
at the third finger of the right hand with an MRI-compatible pulse oximeter (8600FO
MRI, Nonin Medical Inc., Plymouth, MN, USA). Collection of an image took
approximately 1.25 minutes. Respiration was monitored with a strain gauge around the
upper abdomen and ETCO2 data were collected as described during the Lab session.
Additionally, a T1-weighted structural image was acquired with a 3D MPRAGE pulse
sequence for determination of GM, WM, and cerebrospinal fluid volume (repetition time
= 2.3 ms, echo time = 30 ms, flip angle = 9°, voxel dimensions = 1.0 x 1.0 x 1.0 mm).

4.2.3 Data Analysis
Baseline ETCO2 values from the MRI were corrected to Lab values. The length of the
hose to the CO2 analyzer (located outside the MRI area) resulted in a damping of the
signal that significantly diminished the baseline values. Since there was no difference in
respiration rates between the Lab and MRI day we corrected MRI values to the average
baseline Lab ETCO2. The MCA CSA was measured manually by two blinded observers
using Osirix imaging software (Pixmeo, Bernex, Switzerland) and the data from both
observers was averaged and reported. The agreement between the two observers was very
good (intraclass correlation coefficient (ICC) was 0.987 (p<0.001)). The reported CSA
during HC is the maximal value from the five minute period and this is reported along
with percent change (%Δ) from baseline. All other reported variables for HC correspond
to this maximal CSA value. When reported, the MCA diameter was calculated from the
measured CSA. Cerebral blood flow was calculated as CBF (ml/min) = CBFV
(cm/s)*CSA (cm2)*60 (s/min). Cerebral blood flow velocity and CBF are also reported as
%Δ. Cerebral blood flow velocity and MCA CSA were collected at the same time of day
on separate days and, on average, the interval between each test was 11 ± 11 days.
Using SPM 8 (http://www.fil.ion.ucl.ac.uk/spm/), high-dimensional spatial
normalization was performed with T1 images using the DARTEL toolbox. A template
was created by averaging data from all subjects. Images were then segmented into GM,
WM and cerebrospinal fluid. Total intracranial volume was calculated as the sum of these
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three components. Since GM volume has been documented to change the most with age
we normalized all measurements of CBFV, CBF, CVC, and CVR to GM volume and are
reported as CBFVGM, CBFGM, CVCGM, and CVRGM.
Cerebrovascular conductance was calculated as the quotient of CBFGM and MAP.
Cerebrovascular reactivity indices were calculated both as the percent and absolute
change in CBFGM and CBFVGM per mmHg change in ETCO2 at approximately every
1.25 minutes during HC (to correspond with the timing of MCA images). The right and
left common carotid artery intima-media thickness was quantified with calipers at three
regions along the artery and averaged. An independent observer also completed the
analysis and the ICC between the observers was 0.985 (p<0.001). An average from the
two investigators is reported.

4.2.4 Statistical Analysis
The effects of time (baseline versus hypercapnia) and group (YA versus OA) were
assessed using a general linear mixed model ANOVA and a Holm-Sidak post hoc test for
pairwise comparisons (SigmaStat 12.0; Systat Software, San Jose, CA) for heart rate, BP,
ETCO2, respiration, MCA CSA, CBFVGM, CBFGM, CVCGM, and CVRGM. Unpaired ttests were used to assess the impact of group on GM, WM and cerebrospinal fluid. The
probability level for statistical significance was p≤0.05.

4.3 Results
On average, OA had greater systolic BP, fasting glucose, total and LDL cholesterol,
triglycerides and hemoglobin A1C levels than YA but were still within the normal range
(Table 4.1). On separate testing days (Lab and MRI) there were no differences in seated
BP in YA or OA prior to beginning experimental protocols. Additionally, OA had greater
intima-media thickness of the left and right common carotid arteries (Table 4.1). There
were no differences in MoCA scores or Part B of the Trail Making Test between groups.
Time to complete Part A of the Trail Making Test was 26 ± 10 s for the OA and 19 ± 6 s
for the YA (p=0.07). Testosterone levels in older postmenopausal women were greater
than YA females (p=0.03; Table 4.2) and 17-β estradiol levels were not detectable in 4 of
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5 OA females. In the female with detectable estradiol the levels were within the
postmenopausal range (<202 pmol/L).
A main effect of time (baseline to HC) was observed for heart rate and ETCO2 in
the Lab and MRI and diastolic BP in the Lab (p<0.001 for all) (Table 4.3). A group x
time interaction was present for systolic BP where baseline (p=0.03) and HC (p=0.002)
systolic BP values were greater in OA versus YA and there was a significant increase
during HC (p<0.001) in OA that was not present in YA. There were also main effects of
time (p=0.003) and group (p=0.002) for MRI respiration where respiration was greater in
YA compared to OA.
There was a significant effect of time (baseline to HC) when absolute MCA CSA
was compared to baseline but no effect of group was observed (Figure 4.1C).
Specifically, in YA, MCA CSA increased from 6.5 ± 1.6 to 7.1 ± 1.4 mm2 with HC while
OA CSA changed from 7.0 ± 1.2 to 7.3 ± 1.4 mm2 (Figure 4.1A and B). A significant
difference between YA and OA was observed in %Δ CSA (p=0.04; Figure 4.1D).
Grey matter volume was decreased in OA compared to YA (p=0.008) while WM
volume was not different (Table 4.4). Compared to YA, cerebrospinal fluid volume was
increased in OA (p=0.02) but the total intracranial volume was not different between
groups. A main effect of time (p<0.001) but no effect of group was observed for
CBFVGM where HC was greater than baseline. Similarly, for CBFGM there was a main
effect of time (p<0.001) and no effect of group. There were significant differences in both
YA (p<0.001) and OA (p=0.04; Figure 4.2C) when the %Δ was compared for CBFVGM
and CBFGM where CBFVGM was lower than CBFGM.
At baseline and during HC MAP was greater in OA than YA (p=0.01 at baseline
and p<0.001 during HC; Figure 4.3A). Mean arterial pressure during HC was also greater
than baseline levels within each group (p=0.02 in YA and p<0.001 in OA). At baseline
there was no difference in CVCGM between YA and OA (Figure 4.3B). During HC,
CVCGM was elevated in YA compared to OA (p=0.02). Additionally, within group
differences in CVCGM were present during HC compared to baseline where there was an
increase in CVCGM with HC (YA: p<0.001and OA: p<0.001).
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Cerebrovascular reactivity was determined in absolute and relative terms using
both CBFVGM and CBFGM. There was no effect of group (YA versus OA) but a
significant difference where CBFVGM was lower when CBFGM was used for absolute
CVRGM (p<0.001; Figure 4.4A). Relative CVRGM calculated with CBFVGM was
decreased compared to the same estimate calculated with CBFGM in YA but not OA
(p=0.001; Figure 4.4B).
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Table 4.1: Subject characteristics.
YA

OA

12, 6/6

10, 5/5

Height (cm)

173 ± 14

171 ± 12

Weight (kg)

69 ± 14

74 ± 14

BMI (kg/m2)

23 ± 3

25 ± 3

Systolic BP (mmHg)

112 ± 9

123 ± 11*

Diastolic BP (mmHg)

72 ± 6

75 ± 11

4.8 ± 0.5

5.4 ± 0.4*

3.92 ± 0.50

5.00 ± 0.77*

HDL cholesterol (mmol/L)

1.50 ± 0.46

1.59 ± 0.45

LDL cholesterol (mmol/L)

2.10 ± 0.47

2.94 ± 0.51*

Triglycerides (mmol/L)

0.70 ± 0.27

1.05 ± 0.48*

0.053 ± 0.002

0.057 ± 0.003*

Right

0.44 ± 0.05

0.73 ± 0.13*

Left

0.48 ± 0.06

0.74 ± 0.17*

28 ± 1

28 ± 2

n, male/female

Glucose (mmol/L)
Total cholesterol
(mmol/L)

HbA1C (mmol/L)
IMT (mm)

MoCA score (out of 30)
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Trail Making Test (s)
Part A

19 ± 6

26 ± 10

Part B

41 ± 13

61 ± 33

Values are mean ± standard deviation. BMI = body mass index; BP = blood pressure;
HbA1C = hemoglobin A1C; HDL = high density lipoprotein; IMT = intima-media
thickness; LDL = low density lipoprotein; MoCA = Montreal cognitive assessment; OA
= older adults; YA = young adults. *p<0.05 versus YA.
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Table 4.2: Sex hormones in young and older adults.
YA

OA

Males

Females

Males

Females

(n=6)

(n=6)

(n=5)

(n=5)

17-β Estradiol (pmol/L)

79 ± 28

125 ± 28

106 ± 34

N/A*

Progesterone (nmol/L)

2.4 ± 1.3

1.6 ± 0.8

1.3 ± 0.6

0.8 ± 0.5

Testosterone (nmol/L)

18.5 ± 6.3

0.9 ± 0.4

18.3 ± 7.8

0.5 ± 0.2†

Values are mean ± standard deviation. *Four of five postmenopausal women had 17-β
estradiol levels lower than the assay could detect (<19 pmol/L) while the remaining
woman was 47 pmol/L. OA = older adults; YA = young adults. †p<0.05 versus YA
females with t-test.
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Table 4.3: Physiological characteristics at baseline and hypercapnia for Lab and MRI.
YA
Baseline

HC

OA
Baseline

HC

P-value
Time

Group

Interaction

LAB
Heart rate

65 ± 9

71 ± 10

62 ± 11

68 ± 11

<0.001

0.49

0.97

114 ± 10

116 ± 12

124 ± 10*

132 ± 10*†

<0.001

0.07

0.04

68 ± 7

71 ± 7

73 ± 10

77 ± 10

<0.001

0.13

0.29

13 ± 3

14 ± 5

11 ± 3

11 ± 3

0.62

0.07

0.93

38 ± 4

49 ± 4

39 ± 3

49 ± 4

<0.001

0.97

0.95

(bpm)
SBP
(mmHg)
DBP
(mmHg)
Respiration
(breaths per
minute)
ETCO2
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MRI
Heart rate

71 ± 13

78 ± 13

69 ± 15

74 ± 15

<0.001

0.57

0.42

15 ± 3

17 ± 4

10 ± 4

11 ± 4

0.003

0.002

0.83

38 ± 4

51 ± 2

38 ± 3

51 ± 3

<0.001

0.67

0.80

(bpm)
Respiration
(breaths per
minute)
ETCO2

Values are mean ± standard deviation. DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HC = hypercapnia; OA =
older adults; SBP = systolic blood pressure; YA = young adults. *p<0.05 compared to baseline. †p<0.05 compared to YA.
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Table 4.4: Brain volume in young and older adults.
YA

OA

Grey matter (ml)

719 ± 98

622 ± 50*

White matter (ml)

536 ± 60

545 ± 58

Cerebrospinal fluid (ml)

222 ± 37

266 ± 40*

1476 ± 175

1432 ± 131

Total intracranial volume (ml)

Values are mean ± standard deviation. OA = older adults; YA = young adults. *p<0.05
for baseline versus YA.
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Figure 4.1: Middle cerebral artery cross-sectional area (CSA) during hypercapnia in
young adults (YA) and older adults (OA). A: Mean and individual CSA at baseline and
hypercapnia in YA. B: Mean and individual CSA at baseline and hypercapnia in OA. C:
Mean CSA at baseline and hypercapnia in YA and OA. D: CSA percent change from
baseline. *p<0.05 versus YA.
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Figure 4.2: Cerebral blood flow velocity (CBFV) and cerebral blood flow (CBF) during
hypercapnia in young adults (YA) and older adults (OA). A: CBFV at baseline and
hypercapnia in YA and OA. B: CBF at baseline and hypercapnia in YA and OA. C:
Percent change CBFV and CBF with hypercapnia in YA and OA. *p<0.05 versus CBFV.
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Figure 4.3: Mean arterial pressure (A) and cerebrovascular conductance (B) at baseline
and hypercapnia in young adults (YA) and older adults (OA). *p<0.05 versus baseline;
†p<0.05 versus YA.
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Figure 4.4: Cerebrovascular reactivity (CVR) at baseline and hypercapnia in young
adults (YA) and older adults (OA). A: Absolute CVR in YA and OA. B: Relative CVR in
YA and OA. *p<0.05 compared to CBFV CVR.
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4.4 Discussion
The main findings of this study are as follows: 1) The %Δ in MCA CSA with HC was
greater in YA than OA. 2) When corrected to GM volume, MCA flow velocity or blood
flow were not different between YA and OA at baseline or during HC. 3) CBFVGM
underestimated the change in CBFGM with HC in both YA and OA. 4) There was a
greater change in CVCGM during HC in YA than OA. 5) Despite the smaller dilatory
response in OA versus YA, CVR was not different between the groups due to the
compensatory central hemodynamic contributions to CBF through elevated BP in OA.
Therefore, when studying MCA flow patterns, reductions in absolute baseline CBF in
healthy aging are related to reductions in cortical mass. Furthermore, the aging process
appears to include diminished cerebrovascular dilatory responsiveness in the MCA and
its downstream vascular bed. In addition to exposing age-related decrements in CVC,
these data outline the concern that the sole use of CVR to study cerebrovascular health
may be misleading due to compensatory responses that can elevate CBF despite smaller
dilatory responses.
A major finding of the current study was the smaller dilation of the MCA in OA
in response to HC. The mechanism(s) involved in this impaired dilation is beyond the
scope of this study but may include arterial stiffening or impaired endothelial function as
it pertains to HC or shear stress stimuli. Extracellular pH of the cerebrovasculature is the
main mediator of the HC-induced increase in CBF (64) via an effect on potassium
channels (63) and it is unclear how aging may affect these channels. In addition, NO and
prostaglandins may also play a role in this response (2, 17). Unfortunately, studying
endothelial function in the intact, conscious human brain is difficult though drug studies
have been employed to examine endothelial regulation of the cerebrovasculature. The
hypercapnic increase in CBFV measured with TCD in humans (23) and CBF with the
133

Xe clearance method in rats (28) was impaired with NO synthase blockade, though not

abolished. Additionally, administration of a NO donor to patients with endothelial
dysfunction restores CVR measured with TCD to levels of healthy age-matched controls
(71). However, other studies have found no effect of NO inhibition on the response to HC
in humans (12, 29). It is possible that blockade of one pathway results in upregulation of
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another (for example, the prostaglandin pathway) since it is not the NO pathway alone
that is responsible for the hyperemic response to HC. Additionally, when indomethacin is
administered to block the prostaglandin pathway in humans a difference in YA and OA in
baseline TCD CBFV and CVR is abolished, which indicates that the prostaglandinmediated response to HC is impaired with aging (11).
This study is the first to incorporate direct measures of MCA CSA and CBF
scaled to GM volume in calculations of flow responses in a healthy aging model. A major
outcome of this approach was the observation that healthy aging does not affect CVR.
Previously, reports on the impact of age on CVR were based primarily on mean CBFV
through the MCA (2, 9, 18, 20). Yet, even CVR calculated using CBFV was the same
between groups when normalized to GM volume. Therefore, these data highlight the
importance of considering contributing factors to the flow response. These findings are in
line with other human studies that have reported no difference in CVR with age using
TCD (9, 18). Galvin et al. (2010) and Murrell et al. (2013) found no difference in CVR
between young and older groups with a very similar age range to our subjects. However,
MAP during HC was not reported in either of these studies so it is unclear whether a
greater pressor response played a role in maintaining CVR in OA as we suggest based on
our data. These studies also reported an increase in cerebrovascular resistance in the older
participants which is in line with the reduction in conductance during HC that we
observed in OA.
The major outcome of this study was quantification of an age-related reduction in
dilatory responsiveness at the MCA and the downstream vessels that it supplies. These
data confirm the findings of Barnes et al. (2012) who drew similar conclusions based on
TCD CBFV measures alone (11). Additionally, Barnes et al. (2012) found no differences
in CVC between young and older adults when indomethacin was administered. These
findings suggest that with age, one pathway that may be altered is cyclooxygenasemediated dilation. Our results add to these findings because they confirm that CVC
calculated based on CBF rather than CBFV is diminished in OA. Also, the impairment in
dilation that results in decreased CVC is not limited to vessels downstream to the MCA,
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but also to the MCA itself. Finally, changes in GM volume with aging cannot account for
the difference in CVC between young and older groups.
The discussion above outlines the problem that measures of CVRGM and CVCGM
support opposing conclusions in the context of studying human cerebrovascular health.
These findings lead to the question of whether CVR or CVC is a more appropriate metric
for examining the dilatory capacity of the cerebrovasculature. A major point here is that
CVR does not measure vasodilation but only the flow response to a stimulus. In turn,
changes in flow can be incurred by either a change in downstream conductance and/or by
a change in the pressure gradient. The cerebrovascular pressure gradient is difficult to
measure in humans but is formed to a large extent by the systemic BP. Nonetheless,
rarely is BP measured or reported in CVR measures despite evidence that HC elevates BP
(13, 20). The current study indicated that the pressor response to HC is greater in OA
compared to YA. By accounting for changes in MAP, the current calculation of CVCGM
exposed the reduced dilatory response in the OA. The effect of MAP on CBFV has been
examined and reported that above a threshold ETCO2, increases in MAP with ETCO2
have a linear relationship with CBFV (13). As well, Claassen et al. (2007) found that the
magnitude of increase in an index of CVC with a rebreathing challenge was greater than
the magnitude of change in CBFV which suggests that MAP has a direct effect on CBFV
(20). Based on these findings and the fact that the change in MAP during HC was
different between groups, we suggest that the best way to rationalize these findings is to
calculate a CVC reactivity index as the change in CVC divided by the change in ETCO2.
When this is done as a percent change in CVCGM there is no difference between YA (4.22
± 1.60 %/mmHg) and OA (3.18 ± 1.34 %/mmHg, p=0.11). However, the difference is
significant using the absolute change in CVCGM (YA: 1.8 x 10-4 ± 0.69 x 10-4
ml/min/ml/mmHg and OA: 1.2 x 10-4 ± 0.56 x 10-4 ml/min/ml/mmHg, p=0.04).
We examined the relationship between GM volume and cerebrovascular indices
based on the idea that there is a linkage between CBF and tissue atrophy. Previous studies
have reported decreased CBFV in OA compared to YA (2, 20, 31) and when we
normalized CBFV to GM volume we did not see differences in CBFVGM, CBFGM, or
CVRGM. However, a difference in CVC between groups was present during HC even
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when normalized to GM volume. One limitation of this normalization approach is that we
used total GM volume though the MCA is not responsible for perfusion of all the GM
and the exact portion of tissue that it supplies is unknown. This estimate was used
because it is difficult to determine exactly which regions are supplied by the MCA due to
individual variation. The challenge of our approach is exposed by Chen et al. (2011) who
examined voxel-wise measures of cortical blood flow using MRI perfusion methods
(arterial spin labelling) and cortical thickness and reported that, on that small scale,
reductions in CBF with aging were dissociated from the concurrent process of cortical
atrophy (18). Therefore, our results suggest that an overall relationship exists between
CBF and GM volume; however, the pattern becomes dissociated at the voxel scale.
Additionally, with this cross-sectional approach we are unable to determine if initial
atrophy results in the flow reduction or a flow impairment leads to atrophy.
In conclusion, this study was the first to show that the MCA and its vascular bed
display impaired dilation to hypercapnia in healthy aging. Our studies indicate that the
measure of CVC and/or CVC reactivity to CO2 is a more appropriate estimate of the
dilatory capacity of the cerebrovasculature than a traditional estimate of CVR.
Additionally, we confirm that there is a relationship between GM volume and MCA CBF
so that a reduction in MCA CBFV and/or CBF with age may be a result of global GM
tissue atrophy, or impaired flow leads to atrophy, and this should be accounted for when
making comparisons between groups.
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Chapter 5

5

General Discussion

5.1 Perspectives
A literature search in PubMed using the search term “transcranial Doppler ultrasound”
elicits a response of almost 8,000 papers. A majority of these papers examine the MCA
and all assume that the diameter of the MCA does not change or that the change is
negligible so CBFV is the same as CBF. Hypercapnia and/or hypocapnia are commonly
used to examine cerebrovascular health where a greater increase in CBFV with HC
and/or a greater decrease in CBFV with HO is a healthier response. Based on evidence
that MCA diameter may not be constant combined (2, 4) with a greater availability of
MRI technology with enhanced resolution we designed this series of studies to examine
how MCA CSA changes with HC or HO. Additionally, we wanted to quantify how
changes in MCA CSA impact estimates of CBF and CVR in young and older
populations. Finally, we examined how changes in MCA CSA compare to those at the
ICA with HC and HO.

5.2 Major Findings
The main finding of this series of studies were that MCA CSA increased during HC and
decreased during HO. When the findings from all three studies using HC (n=36) and the
two studies with HO (n=24) for young adults were combined the average increase was 15
± 8% during HC and the average decrease was 9 ± 6% during HO (Figure 5.1). When
CBFV was compared to CBF during HC, CBFV underestimated the change in CBF.
Also, CVR during HC was underestimated if CBFV was used. In the first study of this
series we documented similar results with HO where CBFV underestimated the change in
CBF and CVR. However, in the second study of this series the difference between CBF
and CBFV was not significant during HO. Additionally, even in OA where the change in
CSA was smaller during HC, this still resulted in a greater change in CBF versus CBFV.
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When the CSA data from all studies are combined (Figure 5.1) an important
observation is that there is variability in the data both in baseline CSA and in the response
HC and HO. Initially, we were hopeful that a universal correction factor could be applied
so that TCD users could correct CBFV measurements based on the amount of change in
ETCO2 to more closely estimate CBF; however this is not practical because of the
variability in the response. For example, in the subject with the largest baseline CSA
(who also had the smallest response to HC), during HC there was no diameter change so
CBFV is equivalent to CBF. However, in the subject with the greatest hypercapnic
response, the MCA CSA change was almost 29% resulting in a 42% difference in
estimates of CBFV and CBF. During HO, there were also subjects who had almost no
constriction at the MCA while the greatest change was a 22% decrease which resulted in
an 11% difference in CBFV and CBF.
Comparison of diameter changes at the MCA to the ICA during HC and HO
revealed that the dilation/constriction response is greater at the MCA as no change was
observed in ICA diameter. This difference was not expected as Willie et al. (2012) had
documented changes in ICA diameter with HO and HC (5). Different exposure times to
HC and HO likely played a role in these observations as we did HC and HO for five
minutes while Willie et al. (2012) applied each stimulus for 12 to 15 minutes before
measurement for CBFV (5). Future studies could examine MCA CSA over longer
exposure to HC and HO. Another notable finding from this study was that at the end of
five minutes, CVR calculated with ICA CBF produced similar estimates to those from
MCA CBF. Since ICA CBF can be quantified with duplex ultrasound and does not
require MRI technology this method of determining CVR is likely more feasible than
performing TCD to determine CBFV and then MRI to determine MCA CSA.
Lastly, CBFV, CBF, and CVR normalized to GM volume were not different
between young and older adults while CVCGM and the percent change in MCA CSA was
greater in YA during HC. In this study, during HC there was a greater pressor response in
OA (7 ± 5 mmHg) versus YA (3 ± 3 mmHg) which we believe compensated for
decreased dilation at the MCA to equalize CBF between groups. Based on these findings,
we suggest that CVC or CVC reactivity (ΔCVC/ΔETCO2) is a more appropriate measure
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to examine the dilatory capacity of the cerebrovasculature as it accounts for changes in
MAP. Even with 4% CO2, Barnes et al. (2012) reported, on average, a change in MAP
from 81 ± 5 to 84 ± 5 mmHg which suggests that even with a smaller stimulus a change
in pressure cannot be avoided (1). Examining the mechanism behind reduced
cerebrovascular dilation was beyond the scope of this research. However, previous work
has implicated a lack of production or utilization of prostaglandins and/or NO in the
response to HC by examining CBFV with TCD (1, 3). Therefore, this same study design
could be used to examine CVC in populations with poor endothelial health, such as those
with atherosclerosis.
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Figure 5.1: Change in middle cerebral artery (MCA) cross-sectional area (CSA) during
hypercapnia (A) and hypocapnia (B).
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5.3 Utility of Transcranial Doppler Ultrasound
It is important to identify how these changes in MCA CSA during HC and HO may
impact the findings of many TCD studies as MRI technology is not as widely accessible
or feasible. When examining differences between groups and/or experimental conditions
that involve HC or HO it is important to recognize that measured changes in CBFV likely
underestimate actual changes in CBF. However, this is more of a problem when
comparing groups that likely have differences in arterial health. For example, in the third
study in this thesis young and older adults did not have the same dilatory response at the
MCA to HC so we cannot say that CBFV underestimates CBF by the same amount in
each group. Based on our findings in OA we speculate that other groups of older adults
such as those with cardiovascular disease likely have a similar, or possibly even greater,
impairment in MCA dilation. Therefore, when comparing such a group to a young
population it is more important to keep in mind that changes in the MCA are likely
different between groups. In terms of HO, the constrictor response at the MCA was
smaller than the dilatory response to HC so changes at the MCA have less of an impact
on CBF with HO. For instance, in the second study of this thesis when the changes in
CBFV versus CBF were compared over five minutes, no significant changes in HO CSA
were detected until minute four. Therefore, for the first three minutes of HO there is little
difference between CBFV and CBF. Consequently, employing HO protocols that are
shorter in duration is the best way to minimize differences in CBFV versus CBF.
Additionally, if the study population consists of all OA then we have established that
there is less CSA change even with HC so in this case CBFV is a better indicator of CBF.
Finally, TCD is unmatched in its time resolution. In our studies, a difference in
MCA CBFV could be observed within 30 seconds of initiation of HC or HO and tracked
beat-by-beat. This is in contrast to our MRI measurement of phase contrast CBFV that
took approximately 2.5 minutes to create the velocity profile over one cardiac cycle or
our measurement of CSA that could be captured every 1 to 1.25 minutes. Therefore, the
aim of these studies was not to imply that TCD is not a useful tool but to encourage
examination into some of the basic assumptions of the technique. Application of TCD
during changes in ETCO2 can still be encouraged though possible changes in diameter
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should be considered in terms of designing a study that minimizes the impact of these
changes so that CBFV more closely predicts CBF.

5.4 Conclusions
In young adults, the MCA dilates by the first minute of hypercapnia and this dilation
means that CBFV underestimates both CBF and CVR. In contrast, the MCA does not
constrict during hypocapnia until the fourth minute and the impact of this constriction on
estimates of CBF and CVR is less than that of hypercapnia. In addition, constriction and
dilation at the MCA is unmatched by similar responses at the ICA. Finally, the CVR
response to hypercapnia is preserved in healthy older adults, compared to young.
However, impaired MCA dilation and CVC in older adults suggests that the dilatory
capacity of the cerebrovasculature is impaired in comparison to young adults. Therefore,
we suggest that CVC or CVC reactivity is a more telling estimate of the health of the
cerebrovasculature than CVR.
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LETTER OF INFORMATION
Project Title: Examining flow and diameter in the middle cerebral artery during different
levels of carbon dioxide, lower body negative pressure and nitroglycerin.
Principal Investigator: J. Kevin Shoemaker, Ph.D.
Research Coordinator: Nicole Coverdale, M.Sc.
Katelyn Norton, M.Sc.
Carly Barron, M.Sc.
Sponsor: CIHR team grant in physical activity, mobility and neural health
This letter of information is part of the process of informed consent. It should give you an
understanding of the research being conducted and what your participation will involve.
If you would like more details regarding something mentioned in this letter, or
information not included here, please ask. Take time to read this carefully and to know
the following information. You will receive a copy of this form to keep as your own.
Introduction
You are invited to voluntarily participate in a research study that examines how blood
vessels in your brain respond to different protocols by using imaging techniques. A
variety of stressors change blood flow in the brain and it is currently unclear whether this
is because the large blood vessels are changing diameter in response to such stressors.
Therefore, the main purpose of the study is to measure the diameter of and flow through
larger brain vessels with magnetic resonance imaging (MRI). As well, a type of
ultrasound called transcranial Doppler (TCD) is commonly used to study brain blood
flow often based on the assumption that large vessel diameter does not change.
Therefore, a secondary purpose of this study is to validate TCD measures of blood flow
velocity against MRI measures. The study contains three parts that will be conducted on
three separate days. A total of 60 participants will be recruited in this study. If you agree
to participate, you will be required to come to the laboratory approximately three hours
following a light meal and after having avoided alcohol, Nicorette gum, coffee, tea, soft
drinks and chocolate for at least 12 hours.
Participant Inclusion/Exclusion Criteria
You will not be included in the study if you are not within the age ranges of 18 and 80
years of age or if you have any of the following: Raynaud’s disease, respiratory illnesses,
glaucoma, claustrophobia, metallic implants or objects in or under your skin. You will
not be included in the study if you are a smoker. In addition, you will not be included in
the study if you are, or think you might be, pregnant. Also, you will not be included in the
study if you have taken phosphodiesterase type 5 inhibitors within the last 24 hours. This
class of drugs includes Viagra, Cialis, and Levitra and are used for the treatment of
erectile dysfunction. There is a risk for decreased blood pressure due to the
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administration of nitroglycerin in this study and ingestion of these types of drugs magnify
this risk. Additionally, since MRI is used in this study, you will not be included in the
study if you are not suitable for MRI based on the following criteria:
MRI exclusion criteria
If you have any history of head or eye injury involving metal fragments, if you have
some type of implanted electrical device (such as a cardiac pacemaker), if you have
severe heart disease (including susceptibility to heart rhythm abnormalities), you should
not have an MRI scan unless supervised by a physician. Additionally you should not have
a MRI scan if you have conductive implants or devices such as skin patches, body
piercing or tattoos containing metallic inks because there is a risk of heating or induction
of electrical currents within the metal element causing burns to adjacent tissue.
Research Tests
If you take part in this study, you will report to the laboratory on separate occasions to
complete two phases (and 3 Days) of the study. The following addresses what will
happen on each day of testing.
Day 1 Instrumentation: Laboratory for Brain and Heart Health, Room 402, Labatt
Health Sciences Building.
For the tests that occur at the Laboratory for Brain and Heart Health you will have the
following devices attached to you/tests performed for data collection:
1. A button ultrasound probe will be held against the temple region of your head that

2.
3.

4.
5.

6.
7.

will determine how fast the blood is flowing through one of the larger vessels in
the brain. This process is known as transcranial Doppler ultrasound.
Small electrodes will be placed on your chest to record the electrocardiogram
(ECG, the heart rate tracing).
A small cuff will be placed around one finger and a blood pressure cuff will be
placed around the upper portion of the same arm. These cuffs are used to measure
your blood pressure. When activated, the finger cuff will inflate with air and you
should feel a pulsating sensation on your finger. During a recording session your
finger may turn slightly blue and feel numb but this quickly goes away when the
cuff pressure is reduced.
An elastic strap will be placed around your chest to monitor changes in breathing
rate and depth. No discomfort or risks are associated with this procedure.
You will be fitted with a small mouthpiece so that you can breathe a mixture of
gas that is mostly oxygen but contains a higher than normal level of carbon
dioxide. Breathing the carbon dioxide will last a minimum of 7 to 8 minutes.
You will be asked to breathe faster than normal, in time with a metronome.
You will undergo a procedure called “lower body negative pressure (LBNP)”. In
this procedure your legs and hips are sealed in a box and a vacuum will create
suction around your lower body to mimic the effects of gravity. This lower body
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suction mimics the effect of upright posture and, depending on the degree of
suction, unloads baroreceptors in the heart and/or in the aortic arch and carotid
sinus. The level of suction that will be used is equivalent to the effect of gravity
when sitting up.
8. An anesthetist will insert a small plastic tube (catheter) into a large vein in your
arm or hand. This catheter will be connected to an intravenous tube through which
the anesthetist will infuse a drug called nitroglycerin (used to treat angina) or a
saline solution that simply mimics the water portion of your blood. Any infusion
will last up to 15 minutes.
9. You will be asked to breathe through an inspiratory impedance threshold device
(ITD) attached to a tube. You will experience some resistance while inhaling
through this device.
Day 1 Experimental Procedures (Summarized in Figure 1)

You will undergo 5 experimental tasks: 1) Breathing higher-than-normal carbon dioxide
(6% CO2, 21% oxygen and balanced nitrogen), 2) hyperventilating (to reduce carbon
dioxide in your blood), 3) LBNP 4) nitroglycerin administration and 5) ITD. Tossing a
coin will randomize the order of the first three protocols.
1. Carbon dioxide: a facemask will be attached through which you will breathe
air with the same amount of oxygen as with normal air but with more carbon
dioxide. Carbon dioxide levels will be monitored from a line attached to the
facemask. After 5 minutes of rest, you will breathe CO2 until end tidal partial
pressure of CO2 (PETCO2) reaches 50 mmHg (about 2-3 minutes), after which
you will continue breathing the gas for 5 minutes for a total of 7 to 8 minutes.
This level of CO2 will make you breathe faster and deeper. Five minutes
recovery will then allow your levels of carbon dioxide to return to normal.
2. Hyperventilation: after a 5 minutes rest period, you will be asked to breathe in
time with a metronome at a rate that is faster than your normal breathing rate.
You will then be given 5 minutes to recover.
3. LBNP: after 5 minutes of rest, suction will be turned on for 5 minutes and this
will be followed by 5 minutes of recovery.
4. Saline and nitroglycerin: in a random assignment (like the tossing of a coin)
saline or nitroglycerine will be infused. Saline will be infused for 5 minutes
and nitroglycerine (0.5 μg/kg/min) will continue for 15 minutes. Five minutes
of recovery will end the test.
5. ITD: You will be asked to breathe through a tube with an attached ITD for 1-5
minutes at rest and during LBNP.
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The protocols will take approximately 75 minutes for the actual experiment plus time for
equipment setup, insertion of the catheter, familiarization with the protocol and recovery
from the nitroglycerin. Also, it is expected that the TCD probe will continually need to be
adjusted slightly to maximize the quality of the signal. Therefore, the entire test time is
expected to be about 3 hours.
Days 2 and 3 Instrumentation: Robarts Research Institute at Western University
For the tests that occur at the Robarts Research Institute you will have the following
devices attached to you/tests performed for data collection:
1. The blood vessels in your brain will be imaged, which means that you will lie on

2.
3.
4.

5.
6.

7.

8.

a table that enters the bore of a 3.0 Tesla whole-body MRI. It can be noisy during
the MRI procedure so you will wear hearing protection (head phones).
A small cuff will be placed around one finger and will measure heart rate.
An elastic strap will be placed around your chest to monitor changes in breathing
rate and depth. No discomfort or risks are associated with this procedure.
You will be fitted with a small mouthpiece so that you can breathe a mixture of
gas that is mostly oxygen but contains a higher than normal level of carbon
dioxide. Breathing the carbon dioxide will last a minimum of 7 to 8 minutes.
You will be asked to breathe faster than normal, in time with a metronome.
You will undergo a procedure called “lower body negative pressure (LBNP)”. In
this procedure your legs and hips are sealed in a box and a vacuum will create
suction around your lower body to mimic the effects of gravity. This lower body
suction mimics the effect of upright posture and, depending on the degree of
suction, unloads baroreceptors in the heart and/or in the aortic arch and carotid
sinus. The level of suction that will be used is equivalent to the effect of gravity
when sitting up.
An anesthetist will insert a small plastic tube (catheter) into a large vein in your
arm or hand. This catheter will be connected to an intravenous tube through which
the anesthetist will infuse a drug called nitroglycerin (used to treat angina) or a
saline solution that simply mimics the water portion of your blood. Any infusion
will last up to 15 minutes.
You will be asked to breathe through an inspiratory impedance threshold device
(ITD) attached to a tube. You will experience some resistance while inhaling
through this device.

Days 2 and 3 Experimental Procedures (Summarized in Figure 1)
You will undergo 5 experimental tasks: 1) Breathing higher-than-normal carbon dioxide
(6% CO2, 21% oxygen and balanced nitrogen), 2) hyperventilating (to reduce carbon
dioxide in your blood), 3) LBNP, 4) nitroglycerin administration and 5) ITD. Tossing a
coin will randomize the order of these tasks.
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1. Carbon dioxide: a facemask will be attached through which you will breathe
air with the same amount of oxygen as with normal air but with more carbon
dioxide. Carbon dioxide levels will be monitored from a line attached to the
facemask. After 5 minutes of rest, you will breathe CO2 until end tidal partial
pressure of CO2 (PETCO2) reaches 50 mmHg (about 2-3 minutes), after which
you will continue breathing the gas for 5 minutes for a total of 7 to 8 minutes.
This level of CO2 will make you breathe faster and deeper. Five minutes
recovery will then allow your levels of carbon dioxide to return to normal.
2. Hyperventilation: you will continue wearing the facemask during this
protocol. After a 5 minutes rest period, you will be asked to breathe in time
with a metronome at a rate that is faster than your normal breathing rate. You
will then be given 5 minutes to recover.
3. LBNP: after 5 minutes of rest, suction will be turned on for 5 minutes and this
will be followed by 5 minutes of recovery.
4. Saline and nitroglycerin: in a random assignment (like the tossing of a coin)
saline or nitroglycerine will be infused. Saline will be infused for 5 minutes
and nitroglycerine (0.5 μg/kg/min) will continue for 15 minutes. Five minutes
of recovery will end the test.
5. ITD: You will be asked to breathe through a tube with an attached ITD for 1-5
minutes at rest and during LBNP.
The protocols will take approximately 75 minutes for the actual experiment plus time for
equipment setup, insertion of the catheter, familiarization with the protocol and recovery
from the nitroglycerin. Therefore, the entire test time is expected to be about 2 hours.

Figure 1. Study protocol.
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Risks
MRI
Part of your participation in this study will involve a research test with Magnetic
Resonance Imaging (MRI) system, a common medical diagnostic tool that uses a strong
magnetic field, a low frequency magnetic field, and a radio frequency field. No X-rays
are used. As with any technology there is a risk of death or injury. For MRI the risk of
death is less than 1 in 10 million and the risk of injury is less than 1 in 100,000. These
risks do not arise from the MRI process itself, but from a failure to disclose or detect MRI
incompatible objects in or around the body of the subject or the scanner room. It is
therefore very important that you answer all the questions honestly and fully on the MRI
screening questionnaire.
Almost all the deaths and injuries related to MRI scans have occurred because the MRI
operator did not know that surgically implanted metal hardware (such as a cardiac
pacemaker) was present inside the subject during the MRI scan. Other remote risks
involve temporary hearing loss from the loud noise inside the magnet. This can be
avoided with ear headphone protection that also allows continuous communication
between the subject and staff during the scan.
For comparison, the risk of death in an MRI is similar to travelling 10 miles by car, while
the risk of injury during an MRI is much less than the risks associated with normal daily
activities for 1 hour.
You may not be allowed to continue in this research study if you are unable to have a
MRI scan because, for example, you have some MRI incompatible metal in your body,
you may be pregnant or attempting to become pregnant, or you may have a drug patch on
your skin that contains a metal foil. Should you require a medically necessary MRI scan
in the future, the final decision as to whether you can be scanned will be made by a
qualified physician considering all the risks and benefits.
Venous Catheter
There is a small risk of bruising or infection when inserting the catheter into your vein.
Some patients may experience mild pain and discomfort and some may feel nauseated or
dizzy when blood is taken.
ECG
The adhesive on the electrodes used to measure your heart rate may cause a small rash to
develop under the electrode. However, this rash should disappear in a day or two.
Blood pressure cuff
There are no known risks of using the finger cuff methods (Finometer) of examining
arterial blood pressure. With the finger cuff the fingertip may turn a little blue and feel
numb during the prolonged test sessions but this resolves immediately when the cuff is
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removed. Standard arm cuff blood pressure measures of arterial pressure will also be
obtained periodically, a method that has no known risks.
Transcranial Doppler ultrasound
There are no known harmful effects with standard diagnostic ultrasound and tonometry as
used in this study.
CO2 Breathing
Breathing a slightly higher level of carbon dioxide may give you a small headache and it
may make you feel breathless. These feelings vanish quickly when you start breathing
room air again.
Lower Body Negative Pressure
As an orthostatic stress, LBNP carries a risk of fainting (syncope). This is particularly
important during prolonged levels (i.e., 5-10 minutes). To reduce the risk of syncope you
will be instructed to inform the experimenters if you feel any of the symptoms of
presyncope (i.e. nausea, light headedness, tunnel vision, blurry vision, excessive heat and
sweat). You will also be monitored throughout the test for the following termination
criteria: systolic blood pressure less than 90 mmHg, sudden reductions in systolic blood
pressure of >20 mmHg, sudden decrease in heart rate or heart rate less than 30 bpm and
symptoms suggestive of impending syncope. There is minimal risk to you for the
duration and level of LBNP used here because mean arterial pressure is minimally
threatened and there is no additional challenge to cerebral perfusion. Also note that
syncope does not develop immediately even in full head-up tilt tests. Moreover, the signs
of imminent syncope generally develop 1-2 minutes prior to the event (i.e., generally,
there is a progressive reduction in blood pressure prior to the sudden hypotension that
marks presyncope). We will monitor you for these symptoms and stop the suction upon
their first appearance.
Inspiratory impedance Threshold Device
There are no known harmful effects associated with breathing through the ITD as used in
this study.
Nitroglycerin
Nitroglycerin may induce headache. A headache occurs in up to 50% of patients as a
result of dilation of brain blood vessels. The headache usually disappears within several
days with continued treatment. Acetaminophen (Tylenol) may be used to treat nitrate
headaches. Other adverse reactions that occur in less than 1% of patients include allergy:
itching, wheezing, tracheobronchitis (inflammation of lower respiratory tract);
cardiovascular: hypotension (low blood pressure), reflex tachycardia (increased heart
rate), palpitations (abnormality of regular heart rhythm), bradycardia (slowed heart rate),
syncope due to nitrate vasodilation has rarely been reported; central nervous system:
headache, weakness, dizziness, apprehension, restlessness; gastrointestinal: nausea,
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vomiting, diarrhea, and abdominal pain; genitourinary: dysuria (difficulty urinating),
urinary frequency, impotence; metabolic: methemoglobinemia (abnormal amount of a
form of hemoglobin is produced); musculoskeletal: arthralgia (joint pain), muscle
twitching; ophthalamologic: blurred vision; respiratory: bronchitis, pneumonia, upper
respiratory symptoms.
Staying still
During the experiment, you have to remain still in a lying down position for 3 hours. You
may develop a sore back in the middle of the experiment. These sensations will diminish
very quickly when you sit up from the bed after the experiment.
Alternatives to Participating
You may choose not to participate in this study.
Benefits to You if You Take Part in the Study
There are no direct benefits to you as a result of the study.
Voluntary Participation
You are encouraged to ask questions regarding the purpose of this study and the outcome
of your testing. Participation in this study is voluntary. You may refuse to participate,
refuse to answer any questions, or withdraw from the study at any time with no effect on
your academic or employment status. We ask that you do not get involved in any other
study while you are involved in this study. However, participation in this study will not
stop you from being involved in future studies. You do not waive any legal rights by
signing the consent form.
Incidental Findings
An incidental finding refers to any unexpected observation made during the course of the
study that may require attention by your doctor. Examples could include high blood
pressure, irregular heart rhythm or a mass observed with MRI. Should an abnormality be
detected during testing, you will be informed and will be encouraged to share this
information with your doctor.
Confidentiality
All information that you provide will be keep strictly confidential. No information that
could reveal your identity will be released to anyone unless disclosure is required legally.
All of the information collected for this study will be stored in a locked filing cabinet that
will only be accessible to the research team. To further protect your anonymity, your
name will be replaced with a subject ID number on all documents. Representatives of
The University of Western Ontario Health Sciences Research Ethics Board may require
access to your study-related records or may follow up with you to monitor the conduct of
the research.
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Compensation
You will be compensated for parking expenses.
Publication of Results
Published results from this study will not identify you by name. New findings from this
study may be forwarded to each interested participant upon request. You may keep a
copy of this letter of information.
Contact Persons
If you have any questions regarding this study, please feel free to contact:
Dr. Kevin Shoemaker
(519) 661-2111 Ex 85759
Room 3110 Thames Hall
Western University

If you have any questions about your rights as a participant or about the conduct of the
study you may contact The University of Western Ontario Office of Research Ethics,
519-661-3036 or email ethics@uwo.ca
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LETTER OF INFORMED CONSENT
Project Title:
Examining flow and diameter in the middle cerebral artery during different levels of
carbon dioxide, lower body negative pressure and nitroglycerin.
Principal Investigator:
J. Kevin Shoemaker, Ph.D.
I have read the letter of information, have had the nature of the study explained to
me and I agree to participate. All questions have been answered to my satisfaction.
SIGNATURES
In the event that abnormal findings are observed during any of the tests, or upon my
wishes, I consent to the release of my medical information to my family doctor or
medical clinic.
Name of Doctor or Clinic

I agree

OR

I disagree

(initial)

Name of participant (Please print)

Signature of participant

Date

(initial)

Name of person obtaining consent

Signature of person obtaining consent

Date
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The APS Journals are copyrighted for the protection of authors and the Society. The Mandatory
Submission Form serves as the Society's official copyright transfer form.

Rights of Authors of APS Articles
For educational purposes only, authors may make copies of their own articles or republish parts
of these articles (e.g., figures, tables), without charge and without requesting permission,
provided that full acknowledgement of the source is given in the new work. Authors may not post
a PDF of their published article on any website; instead, links may be posted to the article on the
APS journal website.
Posting of articles or parts of articles is restricted and subject to the conditions below:











Theses and dissertations. APS permits whole published articles to be reproduced without
charge in dissertations and posted to thesis repositories. Full citation is required.
Open courseware. Articles, or parts of articles, may be posted to a public access
courseware website. Permission must be requested from the APS. A copyright fee will
apply during the first 12 months of the article’s publication by the APS. Full citation is
required.
Institutional websites. The author’s published article (in whole or in part) may not be
posted to an institutional website, neither at the institutional nor departmental level. This
exclusion includes, but is not limited to, library websites and national government
websites. Instead, a link to the article on the APS journal website should be used. (See
also the APS Policy on Depositing Articles in PMC.)
Institutional repositories (non-theses). The author’s published article (in whole or in part)
may not be posted to any institutional repository. This exclusion includes, but is not
limited to, library repositories and national government repositories. Instead, a link to the
APS journal website should be used. (See also the APS Policy on Depositing Articles in
PMC.)
Author’s article in presentations. Authors may use their articles (in whole or in part) for
presentations (e.g., at meetings and conferences). These presentations may be
reproduced (e.g., in monographs) on any type of media including, but not limited to, CDs,
DVDs, and flash drives, for educational use only in materials arising from the meeting or
conference such as the proceedings of a meeting or conference. A copyright fee will
apply if there is a charge to the user or if the materials arising are directly or indirectly
commercially supported.
Reuse in another journal before final publication is prohibited. Permission for reuse of an
article (whether in whole or in part) in another publication is restricted to the finalpublished version of the article. If an article is currently published on the APS "publish
ahead of print" website (Articles in PresS), then the author must wait to request
permission to reuse the article, or any part of the article, until such time when the article
appears in final-published form on the APS journal website.

Authors who do not have access to a subscription and/or who are not APS members may:



purchase the article through the pay-per-view option, or
purchase a Toll-Free Link from APS, which will allow them to post a link to the APS
journals website (directly to the article) enabling unlimited free downloads for any user
accessing the article via this Toll-Free Link.
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